Study  Title  Randomized  Crossover Euglycemic 
Clamp Study in Adult Patients with 
Type [ADDRESS_957249] Number  [STUDY_ID_REMOVED]  
Document  Description  CLINICAL  INVESTIGATION  PLAN  
Document  Date  24 November 2020  

Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed i Randomized Crossover Euglycemic Clamp Study in Adult 
Patients with Type 1 Diabetes  
to Assess Pharmacokinetics and Pharmacodynamics of 
Subcutaneously Infused Insulin  
Using an Investigational Extended Wear  
Continuous Subcutaneous Insulin Infusion Cannula 
Compared to a Commercial Infusion Set 
Protocol Number: 150- 1022- 00 
Revision:  F 
24 November 2020 
National Clinical Trial (NCT) Identified Number : [STUDY_ID_REMOVED]  
Principal Investigator:
[INVESTIGATOR_91648] S. Bailey, MD (AMCR Institute, Escondido, CA) 
Sponsor: Capi[INVESTIGATOR_171642], Inc. 
Funded by: [CONTACT_704478] 2R44DK110969- 02 
Summary of Changes from Previous Version: 
Affected Section(s)  Summary of Revisions Made  Rationale  
1.3 Table 2  
5.6 
[IP_ADDRESS]  
[IP_ADDRESS]  Clarify procedure; added one time rescreen for A1C and 
C-peptide Align to Study Center 
procedure; Capi[INVESTIGATOR_704458]’s standard 
procedure has been to 
allow for a single rescreen 
attempt for key labs (e.g. 
A1C and c -peptide).  
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed ii TABLE OF CONTENTS 
STATEMENT OF COMPLIANCE  ............................................................................................................................. 1  
1 PROTOCOL SUMMARY  ............................................................................................................................... 2  
1.1 Synopsis  ................................................................................................................................................ 2  
1.2 Schema  ................................................................................................................................................. 8  
1.3 Schedule of Activities (SoA)  ............................................................................................................... 9  
2 INTRODUCTION  .......................................................................................................................................... 11 
2.1 Study Rationale  .................................................................................................................................. 11 
2.2 Background ......................................................................................................................................... 11 
2.2.1  Preliminary Data  ............................................................................................................. 11 
2.2.2  Human Use  ..................................................................................................................... 12 
2.2.3  Relevant Literature  ......................................................................................................... 12 
2.2.4  Clinical Need  ................................................................................................................... 16 
2.2.5  Treatment Issues  ........................................................................................................... 17 
2.3 Risk/Benefit Assessment  .................................................................................................................. 17 
2.3.1  Potential Risks  ................................................................................................................ 17 
2.3.2  Known Potential Benefits  .............................................................................................. 20 
2.3.3  Risk Benefit Analysis  ..................................................................................................... 20 
3 OBJECTIVES  ................................................................................................................................................ 23 
3.1 Primary Objective  .............................................................................................................................. 23 
3.2 Secondary Objectives  ....................................................................................................................... 23 
3.3 Safety Objectives  ...............................................................................................................................  24 
4 STUDY DESIGN  ........................................................................................................................................... 24 
4.1 Overall Design  .................................................................................................................................... 24 
A4.1.2 Achilles Infusion Set Device Description  .................................................................... 24 
A4.1.2 Indication/Intended Use  ................................................................................................  25 
A4.1.3 Cautions, Warnings and Precautions  .......................................................................... 25 
4.2 Scientific Rationale for Study Design .............................................................................................. 26 
4.3 Justification for Dose  ......................................................................................................................... 26 
4.4 End of Study Definition  ..................................................................................................................... 27 
5 STUDY POPULATION  ................................................................................................................................  27 
5.1 Informed Consent  .............................................................................................................................. 27 
5.2 Inclusion Criteria  ................................................................................................................................  27 
5.3 Exclusion Criteria  ...............................................................................................................................  28 
5.4 Study Visit Exclusion Criteria  ........................................................................................................... 30 
5.5 Lifestyle Considerations  .................................................................................................................... 31 
5.6 Screen Failures  .................................................................................................................................. 31 
5.7 Strategies for Recruitment and Retention  ...................................................................................... 31 
6 STUDY INTERVENTION  ............................................................................................................................ 31 
6.1 Study Intervention Administration .................................................................................................... 31 
6.1.1  Study Intervention Description  ..................................................................................... 31 
6.2 Preparation/Handling/Storage/Accountability  ................................................................................ 39 
6.2.1 Formulation, Appearance, Packaging, and Labeling  ................................................ 39 
6.2.2 Preparation  ...................................................................................................................... 40 
6.2.3 Achilles Infusion Set Device Accountability ................................................................  40 
6.3 Measures to Minimize Bias  .............................................................................................................. 40 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F  
Confidential Uncontrolled when printed iii 6.4 Study Compliance .............................................................................................................................. 40 
6.5 Concomitant Therapy ........................................................................................................................ 41 
6.5.1  Rescue Medicine  ............................................................................................................ 41 
7 DISCONTINUATION AND WITHDRAWAL  .............................................................................................. 41  
7.1 Discontinuation of Study Intervention  ............................................................................................. 41 
7.2 Participant Discontinuation/Withdrawal from the Study  ...............................................................  [ADDRESS_957250] to Follow- Up ...............................................................................................................................  43 
8 STUDY ASSESSMENTS AND PROCEDURES  ..................................................................................... 43 
8.1 Efficacy Assessments  ....................................................................................................................... 43 
8.2 Safety and Other Assessments  ....................................................................................................... 43 
8.3 Adverse Events  .................................................................................................................................. 44 
8.3.1  Definition of Adverse Events  ........................................................................................ 44 
8.3.2   Serious Adverse Events and Unanticipated Adverse Device Effects  ................... 44 
8.3.3 Adverse Event/Effect Classification ............................................................................. [ADDRESS_957251]  ........................................................................................... 47 
8.3.9 Reporting of Pregnancy  ................................................................................................  47 
8.4 Unanticipated Problems  .................................................................................................................... 47 
8.4.1 Unanticipated Issue Reporting to IRB  ......................................................................... 48 
8.4.2 Unanticipated Issue Reporting to Participants  ........................................................... 48 
9 STATISTICAL CONSIDERATIONS  .......................................................................................................... 48 
9.1 Statistical Hypotheses  ....................................................................................................................... 48 
9.2 Sample Size Determination  .............................................................................................................. 48 
9.3 Populations for Analyses  .................................................................................................................. 48 
9.4 Statistical Analyses ............................................................................................................................ 49 
9.4.1  General Approach  .......................................................................................................... 49 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 50 
9.4.3  Analysis of the Secondary Endpoint(s)  ....................................................................... [ADDRESS_957252] Policy  .............................................................................................. 57 
10.2  Abbreviations  ...................................................................................................................................... 57 
10.3  Protocol Amendment History  ........................................................................................................... 59 
11 REFERENCES  ............................................................................................................................................. 60 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F  
Confidential Uncontrolled when printed 1 STATEMENT OF COMPLIA NCE  
The trial will be conducted in accordance with International Conference on Harmonization Good Clinical 
Practice (ICH GCP), applicable [LOCATION_002] (US) Code of Federal Regulations (CFR), and the NIH 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Terms and Conditions of 
Award. The Principal Investigator (PI) will assure that no deviation from, or changes to the protocol will 
take place without prior agreement from the abbreviated Investigational Device Exemption (IDE) 
sponsor, funding agency and documented approval from the Institutional Review Board (IRB), except 
where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in 
the conduct of this study have completed Human Subjects Protection and ICH GCP Training. 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval.  Approval of both the protocol and the consent form will 
be obtained before any participant is enrolled.  Any amendment to the protocol will require review and 
approval by [CONTACT_3484].  All changes to the consent form 
will be IRB approved; a determination will be made regarding whether a new consent needs to be 
obtained from participants who provided consent, using a previously approved consent form. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F  
Confidential Uncontrolled when printed 2 1 PROTOCOL SUMMARY 
1.1 SYNOPSIS 
Table 1: Study Synopsis 
Study Title:  Randomized Crossover Euglycemic Clamp Study in Adult Patients with Type 1 Diabetes to 
Assess Pharmacokinetics and Pharmacodynamics of Subcutaneously Infused Insulin Using 
an Investigational Extended Wear Continuous Subcutaneous Insulin Infusion Cannula 
Compar ed to a Commercial Infusion Set  
Short Title:  PK/PD of an Extended Wear Infusion Set for CSII in T1DM Patients (“ PEXIS ”) 
Device 
Description:  The Capi[INVESTIGATOR_171642], Inc. (CapBio) Achilles infusion set is a sterile, non -pyrogenic, 
single use device for continuous subcutaneous insulin infusion (CSII). Achilles infusion sets 
are designed to be used with commercially available infusion pumps (e.g ., Medtronic 
Paradigm). The use of the Achilles infusion set is identical to the commercially available 
MiniMed Silhouette control device. The investigational Achilles infusion set and control 
Silhouette devices differ only in the materials (coil -reinforce d soft polymer vs Teflon) and 
construction (one distal and three side ports vs single distal port, respectively) of the 
indwelling cannula.  
Each infusion set has two basic components: the infusion set body with an indwelling 
cannula and a tubing set for c onnection to the infusion pump reservoir. The Achilles 
infusion set body is provided individually packaged in a sterile pouch. The infusion set 
body is then connected to the tubing set from a commercially available infusion set with 
the proprietary pump re servoir connector (e.g., Medtronic Paradigm) for use with specific 
infusion pumps.  
Device Illustration:  
See document 710 -1021 -00 Achilles Infusion Set, Instruction For Clinical Use.  
Indication/  
Intended Use  The Achilles Infusion Set is intended for the subcutaneous (SC) infusion of medication, 
including insulin, from an external infusion pump.  
Study Description:  This study has been designed as a prospectively enrolled, randomized sequence, [ADDRESS_957253] 
crossover study of device performance, tolerability an d safety of the investigational 
Achilles infusion set or commercial infusion set during two 7 -day home use periods with 4 
in-clinic euglycemic clamp sessions during each of the 7 -day periods. After a wash -out 
period, patients will cross over into the inves tigational or control group, respectively.  

Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F  
Confidential Uncontrolled when printed 3 Hypothesis:  We hypothesize that the rate of decline or slope (s) of natural logarithm of the area under 
the glucose infusion rate curve  AUC 0-300(GIR) over wear time (=4 clamp experiments) will be 
less using the investigational Achilles infusion set compared to the commercial control.  
Statistical hypotheses:  
•Null Hypothesis: There is no difference in the population mean rates of decline for the
Achill es and control infusion sets, as measured by [CONTACT_704479] (s) contrast for the
ln(AUC 0-300(GIR) ) assessed over study days DOI (day 0), day 3, day 5, and day 7.
H0: scontrol = s Achilles  
•Alternative Hypothesis: The rate of decline (slope coefficient s) for th e Achilles
infusion set is less that the corresponding rate for control.
HA: scontrol < s Achilles
Primary Objective  To assess  the reliability of delivery using the investigational Achilles infusion set by 
[CONTACT_704480] 7  (8th calendar day of wear) compared to the commercially available control.  
Primary Endpoint  Rate of decline (s) over wear time (DOI, day 3, day 5, day 7) of  the natural logarithm of the 
area under the g lucose infusion rate curve [ln( AUC 0-300(GIR) )] 
Secondary 
Objective 1:  To assess pharmacodynamic (PD) parameters within and across treatments following 
subcutaneous insulin delivery using Achilles vs Teflon control set on DOI and days 3, [ADDRESS_957254] insertion.  
Secondary 
Endpoints 1:  Mean differences (within treatments over time and between treatments at specified time 
points) in:  
 Time -to-Maximum Glucose Infusion Rate (GIR) (t max(GIR) )
 Time to half -maximal GIR, both early and late (t 50(GIR),early & t 50(GIR),late )
 Onset of action as measured by a drop of blood glucose (BG) by 5  mg/dL
 Duration of insulin action (calculated the same as MRT for PK)
 GIR max
 Area under the GIR curve (AUC 0-t(GIR)), both absolute and as a percentage of
total AUC 0-∞ and Coeffic ient of Variation  (CV) of AUC 0-t(GIR), where
t = 5, 10, 15, 20, 30, 45, 60, 90, 120, 150, 180, 210, 240, and 300 min
Other PD parameters may also be calculated.  
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F  
Confidential Uncontrolled when printed 4 Secondary 
Objective 2:  To assess pharmacokinetic (PK) parameters within and across treatments following 
subcutaneous delivery using Achilles vs Teflon control set on DOI and days 3, 5, and [ADDRESS_957255] 
insertion.  
Secondary 
Endpoints 2:  Mean differences (within treatments over time and between treatments at specified time 
points) in:  
 Early exposure (AUC 0-60min)
 Mean -residence time (MRT) of insulin
 Maximum Insulin concentration (C max)
 Time -to-Maximum Insulin Concentration (t max)
 Time -to-50% Maximum Insulin Concentration [t 50,early & t 50,late ], both early
(i.e. before C max) and late (i.e. afte r C max)
 AUC (0-t) (both absolute and as a percentage of AUC  (0-300)) and Coefficient of
Variability (CV) AUC (0-t) where t =  3, 6, 9, 12 ,15, 20, 25, 30, 35, 40, 45, 50,
60, 70, 80,  90, 105, 120, 150, 180, 210, 240 and 300 min
Other PK parameters may also be calculated.  
Secondary 
Objective 3:  To assess continuous glucose monitoring (CGM) data, comparing data within and across 
treatments.  
Secondary 
Endpoints 3:   Mean daily time in range (70 -180 mg/dL), DOI through Day 7 inclusive
 Mean daily time in target (70-140 mg/dL), DOI through Day 7 inclusive
 Mean and median daily glucose, DOI through Day 7 inclusive
 Glucose variability (%CV), DOI through Day 7 inclusive
 Mean daily time ≤70 mg/dL, <54 mg/dL, DOI through Day 7 inclusive
 Mean daily time >140 mg/dL, >180  mg/dL, >240 mg/dL, DOI through Day 7
inclusive
 Other CGM metrics may also be calculated
Secondary 
Objective 4:  To assess performance of investigational infusion set on DOI through 7 for each treatment  
Secondary 
Endpoints 4:   Proportion of investigational CSII sets that did not fail on each day of use.
 Mean difference across treatments in time to device failure
 Mean difference across treatment in incidence of pump bolus occlusion alarms
 Mean difference across treatment in incidence of pump basal occlusion alarms
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 5 Safety Objectives:  To assess Achilles infusion set safety and tolerability from DOI through day 7 for each 
treatment  
Safety Endpoints:   The occurrence  hyperglycemia  (glucose >250 mg/dL)  not responsive to a pump
bolus dose where response to the bolus is defined as a fall of  at least 50 mg/dL  in
blood glucose within one hour,
 The occurrence  of hyperglycemia  (glucose >250 mg/dL)  after prolonged fasting
(e.g. overnight  or more than 5 hours  following  a meal),  not asso ciated with acute
intercurrent illness, but with a concurrent ketone level ≥0.6 mmol/L.
 Localized infection or inflammation of greater than 1.0 cm in diameter at the
infusion site
 Occurrence of an insulin pump occlusion alarm signal
 Cannula dislodgement from subcutaneous space,
 Cannula malfunction (inability to pi[INVESTIGATOR_704459], bending, kinking, fluid leakage or
other malfunction that might impact insulin infusion)
 Mean visual analog scores (VAS) scores (0 -100 mm) from Day of insertion
through Day 7 of use
 Mean difference of VAS scores (0 -100mm) of CSII investigational sets and CSII
control sets
 Descriptive statistics of per subject term, severity, adverse device effects, and
frequency of adverse events for each treatment
 Descriptive statistics of per subject incidence of unanticipated adverse device
effects
Study Population:  Up to 30 adult participants, with the goal of having approximately 24 completers, may be 
enrolled, ages 18 –70, diagnosed with Type 1 diabetes mellitus (T1DM) who have ≥6 
months experience  using rapid -acting insulin analog delivered via Medtronic MiniMed 
insulin pump and infusion sets.  Only Medtronic pump models 530 and higher may be 
used.  
Study participants will be drawn from existing T1DM patient populations meeting the 
study eligibility  at each study center and from referral practices.  
Phase:  Phase 1b  
Description of 
Sites /Facilities 
Enrolling 
Participants:  This study will be conducted at no more than [ADDRESS_957256] insulin treat ment studies per a standardized euglycemic clamp 
protocol.  
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 6 Description of 
Study 
Intervention:  Existing patient populations at each study center will be screened for study eligibility 
within 28 days of planned study enrollment. Participants without prio r experience using 
the Dexcom G6 will be allowed up to 14 days of a run -in period to familiarize themselves 
with the CGM device. Eligible participants will complete written informed consent and be 
assigned a unique study ID.  
Eligible participants will be randomized for Treatment Period A to either the Achilles 
investigational cannula or a Medtronic Silhouette control cannula using commercially 
available tubing, insulin lispro, insulin pumps and continuous glucose monitoring (CGM) 
equipment. After 2±1 week of washout each participant will enter Treatment Period B for 
a second 7 -day period of catheter wear -time using the other infusion set.  
On Day of Insertion (Day 0), participants will have the investigational Achilles infusion set 
or the control infusion se t inserted by a qualified professional during a clinic visit. 
Participants will undergo training and be provided written instructions if infusion set 
change out is required during the 7 -day wear period.  
At the start of the study, participants will be provi ded with an insulin lispro vial 
(Humalog®, Eli Lilly and Co., Indianapolis, IN), a 23” tubing set compatible with the Achilles 
infusion set and Ascencia Contour Next glucose monitor plus test strips. Participants will 
also wear a study -provided Dexcom G6® (study continuous glucose monitor, to be used in 
real time mode) for the duration of the study.  Participants will manage routine 
basal/bolus insulin therapy using these supplies and their current insulin pump for two 
home use wear periods of up to [ADDRESS_957257] strips will be provided for use in the event of hyperglycemia 
>250  mg/dL.
Visual inspection and photographic documentation of the Achilles  and the comparator  
infusion set insertion site will  be recorded at Day 0. Participants will be asked to conduct 
daily insertion site visual inspection and report/record site reactions, glycemic intervals 
and/or the need for infusion set change out (Days +1 to +7).  
During a 7 -day wear period, participants will undergo 4 in clinic euglycemic glucose 
clamps [Day of Insertion (DOI) and 3, 5, and 7 days later] to assess pharmacokinetics (PK) 
and pharmacodynamics (PD) of a bolus of lispro insulin (0.15  U/kg) when delivered using 
an insulin pump.  
Upon completion  of the first wear period (after 7 days or sooner, in the event that 
infusion set change out has occurred) and a [ADDRESS_957258] a second infusion set inserted by a 
qualifie d professional. Sequence of control and investigational infusion set will be 
randomized.  
It is expected that infusion set change out may be required prior to the end of the 7 day 
wear period. If necessary, participants will follow written instructions for change out to a 
commercial CSII set and return to the study center for visual and photographic evaluation 
of the insertion site. CGM data will be available to the study site in real time (and will be 
reviewed at each clinic visit) by [CONTACT_704481] s oftware to access the individual 
participant’s Dexcom cloud account data. Data will be downloaded from the participant’s 
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957259] 7 -day study 
period will still be eligible to participate in the second study period. End -of-study will 
occur at the end of the second 7 -day study period (or sooner, if infusion set change out is 
required prior to completion of the second 7-day period).  
Study Duration:  Estimated duration of the study is 6 –12 months to allow for patient screening and 
obtaining informed consent from up to 30 potential participants, and 2 treatment periods 
of up to one week (7 days) each.  
Participant 
Duration:  Patient participation is estimated at 7 weeks ( ±1 week): 
 Up to 3 weeks for screening, enrollment/randomization, and 1 week adjustment
period with Dexcom G6® study CGM
 1-week Treatment Period 1;
 2-week washout/rest ( ±1 week);
 1-week Treatment Period 2.
Investigator(s)/  
Study Sites:  Timothy S Bailey, MD  
President & CEO, AMCR Institute  
625 W. Citracado Pkwy, # 112  
Escondido, CA [ZIP_CODE]  
Telephone: [PHONE_14683]  
E-mail: [EMAIL_13473]
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 8 1.2 SCHEMA 
Figure 1: Schematic overview over study design.  

Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 9 1.3 SCHEDULE OF ACTIVITIES (SOA) 
Table 2: Schedule of Activities 
Screening  Treatment Period 1  Washout Period  Treatment Period 2  
Study Visit  Visit 0  Visit 1  Visit 2  Visit 3  Visit 4  Telephone 
Follow -up Washout  Visit 5  Visit 6  Visit 7  Visit 8   Telephone 
Follow -up 
Day -28 to -1 0A 3A 5A 7A 7±1 after 
Period 1  8-28 0B 3B 5B 7B 7±1 after 
Period 2  
Time after CSII  
insertion [h]  72[PHONE_14687]+ 3 168+3 72[PHONE_14687][PHONE_14688]+3 
Procedures  Screening  Rand. /  
Insertion/  
Clamp  Clamp  Clamp  Clamp  Phone call  Routine  Enrollment/  
Insertion/  
Clamp  Clamp  Clamp  Clamp  Phone call  
Example Day of Week  Fri Mon  Wed  Fri Fri Mon  Wed  Fri 
Labs/Questionnaires/Instructions  
Informed consent  X 
Demographics  X 
Medical history  X 
Urine Pregnancy test 1 X X X 
Physical exam  
(incl. height/weight)2 X X 
Concomitant 
medication review  X X X X X X X X X X 
CBC X X 
HbA1c  X 
C-Peptide  X 
Basic Metabolic Panel  X 
ECG X 
Vital signs3 X X X X X X X X X 
Randomization  X 
Patient Instructions4 X X X X X X X X X X 
Adverse event review 
and evaluation5 X X X X X X X X X X 
Device Applications/Removals  
Download Pump and 
SMBG  Data  X X X X X X X X X 
Insert CGM sensor  X X X 
Review CGM data  X X X X X X X X 
Remove Participant’s 
infusion set (AM of 
clamp procedure), 
insert CSII catheter 
(abdomen)  X X 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 10 Remove CSII catheter  
(& insert patient’s 
routine CSII set)  X6 X6 
Clamp  
Switch pump to 0.1  U/h 
at when IV insulin is 
started (evening before 
clamp procedure)  X X X X X X X 
Insert 2 IV cannulas for 
insulin and dextrose 
infusion (evening before 
clamp procedure)  X X 
Prime tubing with insulin 
and connect to CSII 
infusion set and then 
prime cannula  X X 
PK/PD study (run-in, 
bolus, clamp)  X X X X X X X X 
Venous sample 
BG/serum insulin7 X X X X X X X X 
Patient meal (at end of 
clamp procedure)[ADDRESS_957260] required for all female participants of child-bearing age without documented menopausal status or removal of key organs. 
2 Only the Visit 1 body weight value will be used to calculate insulin doses and infusion rates for both treatment periods 
3Vital signs include BP (seated or recumbent), pulse, respi[INVESTIGATOR_7146]; VS should be done every 2 hours ± [ADDRESS_957261] strips will be provided.  
5100 mm Visual Analog Scale (VAS) pain assessment to be performed at Achilles infusion set insertion, daily during home wear period, and at time of Achilles infusion set removal. 
6 End- of-Study (EOS) and Early Termination (ET) Assessments; if participant terminates early because of cannula failure event then glucose clamp will not be done if failed cannula has been removed. Study 
completion time may differ per participant.  Study is considered complete at the end of the second wear period as determined by: (1) Participant has worn Achilles infusion sets for 7 days, (2) Participant 
experiences Achilles set failure requiring change out to commercial CSII set, (3) Participant has hyperglycemic event requiring at home change out to commercial CSII set, or (4) Resolution of device or 
procedure-related AEs.  
7Blood for clampi[INVESTIGATOR_704460] 5-15 min for 300 min   
8Meal and individually determined bolus dose of insulin delivered via pump bolus performed in clinic; participants may be discharged home shortly after meal is completed.  The same meal and insulin 
bolus dose (unless clinically indicated that bolus dose should be modified) to be provided for each participant after all clamp studies  
9 Insertion Site Evaluations for each wear period: Day [ADDRESS_957262]-insertion; Daily during  Day 0 to +7 wear period; Day 7 (or upon infusion set failure) pre-infusion set 
removal, post-infusion set removal.   The site personnel will perform photographic documentation of the insertion site at the time of insertion and at the time of presentation to the study site at the end of 
each wear period. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 11 2 INTRODUCTION 
2.1 STUDY RATIONALE 
Currently, a change of insulin infusion sets is recommended every 72 hours for Teflon sets and every 48 
hours for steel cannulas. Based on clinical experience, there is evidence that cannula wear time might be 
extended in some patients without worsening of glucose control. Other patients report a worsening of 
glycemic control over time, which makes them change the infusion set prior to the recommended 3-day 
time period.  
The objective of this study is to evaluate the insulin pharmacokinetic (PK) and pharmacodynamic (PD) 
performance over the wear duration of the investigational Achilles infusion set (Achilles device) for up to 
[ADDRESS_957263]-insertion relative to conventional Teflon infusion sets. Achilles device functionality, patient 
tolerance and safety events will be collected during routine basal and bolus insulin therapy over the 7-
day home use wear period and 4 in-clinic euglycemic clamp procedures. 
This study was preceded by a clinical study of the Achilles infusion set, 150-1072 Feasibility of an 
Investigational Extended Wear Infusion Set for Continuous Subcutaneous Insulin Infusion (CSII) in 
Patients with Type 1 Diabetes Mellitus. 
We hypothesize that the CapBio Achilles cannula not only provides more reliable insulin delivery (both 
for bolus and basal insulin delivery) but will also demonstrate extended wear time with both improved 
consistency and reliability of insulin absorption. Previous studies have shown that the PK exposure 
profile of rapid acting analog insulin accelerates over 3 days of cannula wear time, indicating a need for 
improved cannula performance over time (see below for literature review). 
2.2 BACKGROUND 
2.2.1  PRELIMINARY DATA 
Insulin absorption from the tissue surrounding a commercial Teflon or steel CSII cannula is slow, 
variable, and unreliable. The majority of CSII cannulas need to be replaced after 2 to 3 days of clinical 
use because insulin absorption from the subcutaneous tissue into the circulation becomes more variable 
and less reliable over time.1–8 An ideal CSII cannula will produce rapid on/off insulin pharmacokinetics 
(PK) and pharmacodynamics (PD) and consistent/precise insulin PK-PD for an extended period of time (7 
+ days). The clinical use of a CSII cannula with rapid on-off PK/PD and low PK variability has the potential
to greatly improve BG control, decrease the risk for hypoglycemia, improve compliance and decrease
costs.9 Overall, insulin infusion sets are the Achilles heel of CSII therapy and a critical barrier to
progress.8
Between 2016 and 2018, CapBio and the Jefferson Artificial Pancreas Center (JAPC, Thomas Jefferson 
University, Philadelphia, PA) performed preclinical studies in 18 swine funded by [CONTACT_704482]: “CSII 
cannula with Rapid On/Off PK-PD, Consistent PK-PD, & E xtended Lifetime to 14 days”. The JAPC research 
team iteratively tested multiple generations of cannulas developed by [CONTACT_704483][INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 12 cannula design that eventually became the Achilles infusion set. This set contains a soft, flexible Nylon 
insulin infusion cannula with wire reinforced walls that prevents kinking, minimizes inflammation and 
increases the surface-area- to-volume ratio (SA:V) of insulin in contact [CONTACT_704484] (1 distal, 3 proximal). The Achilles prototype was well tolerated by [CONTACT_704485] (n=3) 
with no signs of external inflammation or infection. The JAPC was able to show that the Achilles cannula 
design successfully prevented kinking (0% versus 57% kink rate in Silhouette commercial cannulas, 
p<0.001) and that the placement of holes was adequate to ensure that all holes were located below the 
skin for optimal insulin delivery into the subcutaneous tissue. As measured in micro-CT, the SA:V of a 
bolus of insulin/x-ray contrast agent was significantly greater than of a bolus delivered through a 
commercial catheter (+16.5%, p<0.05), suggesting better delivery of insulin into the adjacent tissue and 
vasculature/lymphatics. The JAPC furthermore evaluated tissue response to Achilles cannulas by [CONTACT_8477] s 
of histopathological staining. A layer of thrombus and acute inflammatory tissue formed around each 
CSII cannula due to leakage of plasma and red blood cells and infiltration with neutrophils, macrophages 
and fibroblasts. This layer was consistently thinner around Achilles cannulas compared with the 
commercial Silhouette over 8 days of wear time (p<0.001). The overall area of inflamed tissue 
surrounding the Achilles cannula as measured by [CONTACT_704486] 4 and 8 days of wear time 
(p=0.003). When delivering the bolus, the research team measured tubing pressure using a special setup 
developed at the JAPC. The amplitude and the pattern of the pressure/time curves were found useful to 
differentiate a “normal” insulin bolus delivery into the subcutaneous tissue from an occlusion or a leak. 
Interestingly, there was a statistically significant correlation (R=0.5, p<0.05) between increase in layer 
thickness and increase in pressure, independent of cannula type, suggesting that the layer forms a 
barrier to insulin flow into the adjacent SC tissue. Data were presented at several national and 
international conferences.10–[ADDRESS_957264] been reported to date.   
2.2.3  RELEVANT LITERATURE 
Failure Modes and Failure Rates for Current Infusion Sets: 
The nationwide pediatric surveillance of CSIIs in [LOCATION_013] and Austria reported that 192 (29%) patients 
had no CSII issues at all. However, the other 475 (71%) patients reported [ADDRESS_957265] often 
reported device adverse event was CSII obstruction (33.9%).  A total of 14.2% of the patients reported 
that they had blood in the CSII cannula; 11.1% had skin with redness and 10.1% had bent cannula. It is 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 13 impressive to see that 36.2% of the reported complications occurred by [CONTACT_4475] 1 of CSII cannula usage an d 
82.4% by [CONTACT_171699] 2.13 
Pfützner et al . performed a prospective randomized controlled crossover clinical trial to investigate the 
tolerability of 2-day use of commercial insulin infusion sets in comparison to 4-day use in a real-world 
setting. Twenty-four patients with T1DM managed with an insulin pump were studied during two 3-
month periods.  Outcome measures were glycemic control (SMBG and CGM) frequency and nature of 
device-related and procedure-related adverse events and patient preference. The number of cannula 
related adverse events was 290 with 2-day use versus 495 with 4-day use (P < .05). The overall number 
of treatment related events was 750 with 2-day use versus 934 with 4-day use (P < .001). There was no 
difference in glycemic control between the treatment arms. Treatment satisfaction was higher with 2-
day use (very high/high satisfaction: 90.4% versus 4 day-use: 77.3%, P < .05). The authors concluded that 
using an infusion set for a longer than 2-[ADDRESS_957266] et al.  performed a prospective, two-period, observational, multicenter study in 45 T1DM 
outpatients that managed their diabetes with an insulin pump, CSII cannula and rapid acting insulin. 
During the initial 1-month period the patients used a Teflon cannula (98% of cases) and crossed over to 
an investigational CSII cannula (Accu-Chek FlexLink, Disetronic Medical Systems AG) for a 3-month 
period. The primary endpoint was insertion failure and unexplained hyperglycemia within the first 6h 
after cannula placement. Secondary end points were cannula replacements for unexplained 
hyperglycemia, skin irritation and tissue inflammation. Forty-five initial infusion failures occurred in 14 
patients among 507 commercial Teflon cannula insertions (8.9% of cases), whereas 15 failures were 
seen in nine patients during 488 investigational cannula insertions (3.1% of cases) (P<0.001). The overall 
rate of late cumulative events was 113 of 507 with the commercial CSII versus 66 of 488 using the 
investigational CSII (P<0.001). The occurrence of pain, skin reaction, or redness at the infusion site was 
lower using the investigational CSII cannula.14 
Van Bon et al.  conducted a multi-center trial of 256 patients on three insulins.  Approximately 30% of 
patients experienced at least 1 perceived set failure during the 13-week study period with each insulin. 
More than 60% of patients experienced unexpected hyperglycemia during the 13-week study period. 
These results are similar to experts’ experience managing Type [ADDRESS_957267] of Wear Time on PK/PD and Test Meal Response: 
Clausen et al. observed progressive acceleration of PK exposure over [ADDRESS_957268] challenge and showed substantial declines in glucose 
response between day 1 and day 3 of catheter wear18. This improved glucose response was seen for 
both patch (tubeless) and conventional insulin pump systems, which was presumably a result of 
improved early insulin exposure that occurs over the first [ADDRESS_957269] [expressed as time- to-peak insulin action (t max,IA )] 
and potency [expressed as insulin sensitivity (SI) ] were estimated  during both interventions, and 
correlated with demographic factors such as BMI and glycemic outcomes such as HbA1c. They noted 
that during both interventions, t max,IA was positively correlated with pre- and postintervention HbA1c (r = 
0.50-0.52, p<0.01) and mean glucose (r = 0.45-0.62, P < .05), and inversely correlated with time sensor 
glucose, which was in target range 3.9 to 10 mmol/L (r = −0.64 to −0.47, p<0.05). They observed that 
increased body mass index was associated with higher t max,IA and lower SI (both p<0.05). During closed-
loop insulin delivery, t max,IA was positively correlated with glucose variability (p<0.05) suggesting that 
faster insulin action is associated with improved glycemic control during closed-loop insulin delivery and 
sensor-augmented pump therapy.19 
Experience with extended wear (>3 days): 
Patel et al. performed a randomized crossover clinical trial to compare the performance of Teflon versus 
stainless steel insulin infusion sets in ambulatory humans for up to 1 week.  The study participants used 
a Quick-Set or a Sure-T CSII cannula until the infusion set failed or was worn for 1 week.  All participants 
wore a MiniMed continuous glucose monitoring system for the duration of the study. Infusion set failure 
was defined as an epi[INVESTIGATOR_704461] a correction bolus, 
infection, severe inflammation, or set dislodgement. There were 38 weeks of Sure-T wear and 39 weeks 
of Quick-Set wear with no difference in the survival curves of the infusion sets. There was, however, a 
15% initial failure rate with the Teflon infusion set. After 7 days, both types of infusion sets had a 64% 
failure rate. Eighty-seven percent of the steel sets and 77% of the Teflon sets were functioning after 3 
days (this number includes the 15% that failed on the first day because of kinking), after 5 days 68% of 
the steel and 59% of the Teflon sets were functioning, after 6 days 53% of the steel and 46% of the 
Teflon sets were functioning, and at the end of 7 days 32% of the steel and 33% of the Teflon sets were 
functioning. Overall, 30% failed because of hyperglycemia and a failed correction dose, 13% were 
removed for pain, 10% were pulled out by [CONTACT_21317], 10% had erythema and/or induration of > 10mm, 
5% fell out because of loss of adhesion, and 4% were removed for infection. The main predictor of 
length of wear was the individual participant. There was no increase in hyperglycemia or daily insulin 
requirements when an infusion set was successfully used for 7 days.5 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 15 Alsted studied extended wear of up to 7 days, assessing PK on DOI and days 1, 2, 4 and 7.  Overall PK 
exposure (AUC 0-4hr) was steady over 4 days, with progressive acceleration of t max over that interval 
(p<.02).  By [CONTACT_4475] 7 t max was still accelerated as compared to DOI but, AUC 0-4hr was reduced by 
[CONTACT_3450] 21% (p<.04). The author hypothesized that these changes were due to alterations in local 
adipose tissue blood flow (ATBF) although attempts to measure this directly were inconsistent, with an 
apparent increase in ATBF initially, reverting to baseline by [CONTACT_4475] 4.  Efforts to document increased local 
cytokine levels were hampered by [CONTACT_635577].  ( Alsted TS. Device-induced subcutaneous trauma. 
PhD Thesis.  Department of Histology & Delivery , Novo Nordisk A/S, Denmark & Department of 
Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Denmark, November 2010).   
Summarizing these various studies of cannula wear time, it appears that insulin exposure is accelerated 
during the first few days of CSII cannula wear, and this results in improved response to glucose 
challenge. With further wear time, PK exposure diminishes.  These findings provide challenges for 
persons with diabetes, who may have to adjust insulin doses and meal strategies as insulin exposure 
first accelerates and then wanes over cannula wear time. 
Effect of dispersed insulin delivery on PK: 
Mader et al.  investigated the impact of two different injection strategies on the PK-PD of insulin aspart 
in-vivo in an open-label, two-period crossover study and verified changes in the surface- to-volume ratio 
ex-vivo. Insulin aspart was injected ex-vivo into explanted human abdominal skin flaps. The surface- to-
volume ratio of the subcutaneous insulin depot was assessed by [CONTACT_704487] 1 bolus of 18 IU with 9 dispersed boluses of 2 IU. These two injection strategies were then 
tested in-vivo, in 12 C-peptide –negative type 1 diabetic patients in a euglycemic glucose clamp study for 
8 h after the sc insulin injection(s). The ex vivo experiment showed a 1.8-fold higher mean surface- to-
volume ratio for the dispersed injection strategy. The maximum glucose infusion rates (GIR) were similar 
for the two strategies; however, times to reach maximum GIR and 50% and 10% of the maximum GIR 
were significantly reduced by [CONTACT_10540] [ADDRESS_957270]:  
A second retrospective analysis was conducted by [CONTACT_704488].  on the same dataset involving a 
multicenter closed-loop trial of 32 adults with type 1 diabetes where patients had applied hybrid day-
and-night closed-loop insulin delivery in home-use over 12 weeks.  The objective of the analysis was to 
quantify variability of insulin requirements during closed-loop insulin delivery.   The research group 
retrospectively analyzed overnight, daytime, and total daily insulin amounts delivered.  The coefficient 
of variation was adopted to measure variability of insulin requirements in individual participants.  Data 
were analyzed from 1,918 nights, 1,883 daytime periods and a total of 1,564 days were characterized by 
[CONTACT_704489]-loop use over 85% of time. Their results showed that variability of overnight insulin requirements 
(mean [SD] coefficient of variation 31%) was nearly twice as high as variability of total daily 
requirements (17%, p<0.001) and was also higher than variability of daytime insulin requirements (22%, 
p<0.001), concluding that overnight insulin requirements were significantly more variable than daytime 
and total daily amounts. Ruan further suggested that overnight variability may explain why some people 
with type [ADDRESS_957271] insulin dosing parameters to potentially avoid 
hyper and hypoglycemia patterns.  PK/PD variability across patients, however, continues to affect 
overall glycemic outcomes, and research from Ruan et al.  suggests that the integration of new 
therapeutic modalities and technologies which address more rapid and reliable kinetics could yield more 
consistent and positive glucodynamics/outcomes.  Furthermore, if CGM data could be aggregated to 
generate statistical power within a practice or population, then opportunities emerge to model 
predictive exposure-response relationships of insulin and systemic glucose levels to address inter and 
intra-patient variability and support closed-loop advancements.  
2.2.4  CLINICAL NEED 
Over 1 million people with diabetes globally use an insulin pump, continuous subcutaneous insulin 
infusion (CSII) catheter and rapid acting insulin to manage their BG levels. The majority of patients insert 
a new CSII cannula every 2 –3 days in order to ensure safe and effective BG control.4 Patients find this 
frequent site change and rotation inconvenient and often maintain their infusion site longer than 
recommended.3,4,8 The absorption of insulin from the CSII cannula into the circulation is slow, variable 
and unreliable, especially after using the infusion set for more than 3 days.4  This can lead to dangerous 
and costly complications caused by [CONTACT_157710], hypoglycemia and diabetic ketoacidosis. Patients 
with poor BG control are at increased risk for myocardial infarction, stroke, heart failure, kidney failure, 
peripheral vascular disease, neuropathy, dementia, limb amputation, blindness, and premature death.23 
Furthermore, the repeated trauma of CSII cannula insertion contributes to the development of scar 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 17 tissue and may result in eventual loss of infusion sites.24,25 An ideal CSII cannula will provide rapid on/off 
insulin pharmacokinetics (PK) and pharmacodynamics (PD) and consistent/precise dose to dose insulin 
PK-PD for an extended period of time (> 3 days). The clinical use of a CSII cannula with rapid on-off 
PK/PD and low PK variability has great potential to improve BG control, decrease the risk for 
hypoglycemia, improve patient compliance and decrease costs.8,26,27 The optimized CSII cannula will also 
enhance the safety and performance of a closed-loop AP system, perhaps with a CGM and CSII cannula 
combined into one device capable of a 7+ day wear-time.9  
2.2.5  TREATMENT ISSU ES 
This study will compare the safety and efficacy of the Capi[INVESTIGATOR_171642], Inc. investigational Achilles 
infusion set to a commonly used commercial control Teflon infusion set (Medtronic Silhouette) in adult 
T1DM participants during two wear periods for up to 7 days in each period.  Traditional metrics of 
safety, reliability, insulin PK/PD and glycemic control will be compared using a randomized cross-over 
study design, with each study participant used as their own control.  Infusion set functionality, safety, 
and patient tolerance will be evaluated. The study design is similar to study methods that have been 
used in the evaluation of other CSII sets.  
2.3 RISK/BENEFIT ASSESSMENT 
2.3.[ADDRESS_957272] of anticipated adverse events and study definitions can be found in Section 8.3 of 
this protocol. There may be other risks that are unknown at this time and new risks that may be 
identified during the study. 
Fingerstick 
Fingerstick BG tests may produce pain and/or bruising at the test site.
Diabetes Disease Risks 
Hypoglycemia and associated symptoms such as sweating, trembling, difficulty thinking and
dizziness
Hyperglycemia
Diabetic ketoacidosis
Coma
Death
Insulin pump Use/Therapy 
•Slight bruising at the site of insertion (common)
•Slight discomfort at the time of insertion of the insulin delivery cannula (common)
•Bleeding at insertion site (rare)
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 18 •Clinically significant infection or inflammation at the site of insertion (very rare), due to the
extended cannula wear time this risk might be slightly higher but is considered to occur only rarely.
•Allergy to insulin (very rare)
Note:  Participants will be instructed to regularly check the insertion site for any skin reactions. Skin 
reactions shall be noted in the provided diary and the study team shall be contact[CONTACT_704490].  
Commercial CSII Catheter Insertion Site Reactions 
•Reddening
•Induration
•Purulence
•Itching
•Other non-specified skin irritation
Venipuncture and IV catheter insertion  
•Localized infection – an infection in the tissue around the site
•Phlebitis – inflammation of the wall of the vein
•Hematoma – an accumulation of blood within the tissues that clots to form a solid swelling
•Fatigue caused by [CONTACT_704491] (insulin and glucose concentration
determination)
•Thrombus formation and necessary insertion of a new IV catheter
Continuous Glucose Monitoring Risks 
•Trivial discomfort at the time of insertion of CGM (common)
•Slight bruising at the site of insertion (unlikely)
•Bleeding at insertion site (rare)
•Infection at the site of insertion (rare)
Humalog (insulin lispro injection, USP [rDNA origin]) for injection (ID: 3273563) 
•Allergy
•Anaphylaxis
•Antibody Production
•Hypokalemia
•Lipodystrophy
•Peripheral Edema
•Renal or Hepatic Impairment
•Weight gain
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957273] 6 months of experience with insulin pump therapy. These criteria were set to minimize risk. 
Additionally, screening assessments will be applied to exclude patients with anemia or known 
cardiovascular disease who may be at greater risk of procedure-induced anemia or whose hypoglycemia 
symptoms may be masked by [CONTACT_12382]. (See section 5 for inclusion and exclusion 
criteria.)  
Potential risks associated with Achilles infusion set use and/or extended wear include but are not limited 
to the following:  
Infusion Site Reactions 
•Localized pain
•Bleeding
•Bruising
•Induration
•Infection
•Itching/ Pruritus
•Purulence
•Reddening (erythema)
•Swelling
•Other
•Non-specified irritation
Infusion Set Issues 
•Infusion Set Failure
•Infusion Pump Failure
•Infusion pump dosing error
Achilles Device Related Risks 
•Cannula Kinking
•Insulin leak from site
•Insulin leak from set or tubing
•Adhesive failure
•Cannula dislodgement
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 20 •Cannula insertion failure (not all holes below epi[INVESTIGATOR_49196])
•Incomplete tubing prime
•Incomplete cannula prime
•Air Bubbles in tubing
•Defective venting in insulin pump / reservoir / infusion set connection
A list of anticipated adverse events (AAEs) and study specific definitions can be found in Cap Bio Study 
[ADDRESS_957274], V2. 060619 (Protocol Attachment 
A).  There may be other risks that are unknown at this time and new risks that may be identified during 
the study. 
2.3.2  KNOWN POTENTIAL BENEFITS 
Study participation may not provide any immediate benefit to study participants. However, results of 
this research may result in the following potential benefits to the study participants or to future 
diabetes patient s: 
Development of an extended wear CSII set
Reduction in the number of required CSII set insertions/reduction of number of insertion sites
Reduction in insertion site (skin/tissue) reactions
Improved glucose control (e.g., more stable insulin kinetics)
Improved CSII and insulin pump therapy options
Furthermore, the study adds knowledge to recommendations regarding the timing of infusion set 
changes in insulin pump therapy and potentially reduced injection site reactions. 
2.3.3  RISK BENEFIT ANALYSIS 
This study includes T1DM participants who undergo routine diabetes treatment and glucose control 
methodology.  A standardized study protocol, case report forms, study and investigational device use 
training will be provided to all study investigators/staff and study participants prior to any study related 
intervention or testing. 
The study population consists of adult volunteer participants who have been diagnosed with T1DM, and 
have used an insulin pump for at least [ADDRESS_957275] 6 months of experience with pump therapy will be enrolled to 
minimize the risk of pump use errors.  Each potential study participant will be required to submit a 
minimum of 14 days of pump data to confirm pump use compliance. Patients who routinely wear their 
infusion set for > 4.5 days will be excluded from participation to ensure a homogenous patient 
population of participants who adhere to infusion set labeling restrictions. Screening including physical 
exam, ECG and laboratory testing will rule out patients with anemia or known cardiovascular disease 
who may be at greater risk of procedure-induced anemia or whose hypoglycemia symptoms may be 
masked by [CONTACT_12382]. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 21 The primary risks associated with extended wear of the Achilles infusion set are increased risk of 
hyperglycemic or hypoglycemic epi[INVESTIGATOR_49591]/or infusion site irritation or infection. To ensure patient 
safety while using the newly developed infusion sets, patients are required to wear a CGM sensor 
throughout the study. Only patients with at least 3 months of CGM experience will be recruited. The 
personal CGM should be set with alarm systems engaged throughout study duration. Study staff will be 
able to monitor each patient’s interstitial glucose remotely and will be notified via text in case of alarm. 
Participants will be instructed to contact [CONTACT_704492]. 
Commercial subcutaneous insulin infusion sets have a known failure rate of approximately 15 - 25% 
prior to their labelled 3 day (72 hour) wear duration. Therefore, T1DM patients are accustomed to 
frequent change outs with commercial infusion sets. In response to these known issues, the Capi[INVESTIGATOR_704462] a kink-resistant coil-reinforced soft polymer cannula. This 
cannula contains one distal and three proximal holes to ensure redundancy and extended wear-time of 
up to [ADDRESS_957276] commercially 
available set to maintain CSII therapy. This is the same risk associated with a use of commercially 
available infusion sets. 
CSII set infusion site irritation and infection are familiar risks to insulin pump users. The investigational 
Achilles infusion set will be manually inserted and secured (taped) to an appropriately selected body 
location by a trained study staff member.  Participants will be observed at the study center for 3 hours 
to ensure initial Achilles infusion set function prior to clinic discharge and start of home-use period. 
Study staff may attempt infusion set insertion three times. If insertion is not successful after 3 attempts, 
the Achilles infusion set is considered failed for this study participant. 
Study participants will be instructed to check the infusion site for any skin abnormalities on a daily basis. 
All findings of skin irritation/infection (including tape reactions or cannula dislodgement) will be 
carefully monitored and recorded in a participant diary.   If there is evidence of an infection at the 
infusion site, participants will be instructed to remove the infusion set and insert a fresh insulin infusion 
set as per their clinical routine. The Achilles infusion set will be placed in a provided container and 
biohazard bag. Participants are instructed to photograph the inflamed infusion site and contact [CONTACT_704493].  
As per routine pump therapy, participants will be instructed to closely monitor their blood glucose levels 
during the home wear period using standardized methods including SMBG, CGM, patient diaries, etc. 
Risks associated with extended Achilles infusion set/cannula use will be carefully monitored by [CONTACT_704494], and documented daily in a patient diary.   The insertion sites for both the 
Achilles and comparator set will be visually inspected and photographed pre- and post- infusion set 
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957277] information will be provided in the case of Achilles device issues (site 
infection, infusion set failure, or need for cannula replacement). Any new risks identified during the 
study period will be promptly communicated to the investigational sites. 
Alternate treatment with a commercial infusion set is available to study participants at any point during 
the feasibility evaluation and is not considered to increase participant risk. All other therapy will be 
conducted per standard of care for T1DM patients. 
Risk Benefit Statement 
Insulin infusion sets fail early and fail often. Research from Stanford University found that the majority 
of infusion set failures are due to cannula kinking or a clogged insulin port (see Table 3). This high failure 
rate prevents wider adoption of insulin pump therapy that could improve current patient outcomes and 
expand pump access to users still depending on multiple daily manual injections. 
Table 4: Infusion Set Failure Rate by [CONTACT_704495] (s) of Use  Failure Rate  
Day 1  > 15%
Day 3  > 25%
Day 7  > 65%
This high failure rate prevents wider adoption of insulin pump therapy that could improve current 
patient outcomes and expand pump access to users still depending on multiple daily manual injections. 
Recent data (discussed below) indicate that this 65% failure rate at seven days likely overstates the 
actual failure rate likely to occur when using the Silhouette infusion set for up to seven days. In the Patel 
study, out of eighty possible seven-day wear periods in the twenty study participants studied, infusion 
set failure was attributed to non-correctable hyperglycemia in only 30% of the wear periods (regardless 
of infusion set type).  Other modes of failure were noted to account for the remaining failure events 
(infusion site erythema, infection, infusion site pain, accidental removal, adhesive failure).  Thus, one-
half of the infusion sets that did not perform through seven days were removed for reasons other than 
hyperglycemia. 
15% of Teflon sets (Medtronic QuickSet) used in the Patel study were removed due to kinking upon 
insertion, which was diagnosed within the first few hours of use by [CONTACT_704496] a pump occlusion alarm.  This suggests that only about 23% of sets in the study (30% 
of steel infusion sets and 15% of Teflon infusion sets) failed due to uncorrectable hyperglycemia 
occurring after the first few hours of wear time.  No cases of ketosis were reported in the study, 
meaning that study participants were able to detect and attempt to correct hyperglycemia before the 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 23 development of more serious metabolic derangement.  It should be noted that the paper was published 
in 2014, well before the introduction of more sophisticated and accurate CGM systems that are now in 
use. 
Recent data presented in February 2020 in Madrid by [CONTACT_704497] a 49% survival rate at seven 
days for the QuickSet (as compared to 32% in the Patel study), again suggesting that the expected failure 
rate in the control arm of the proposed study is not likely to be as high as that observed in the Patel 
study. 
Therefore, the risk associated with infusion failure in the control arm with extended use for up to seven 
days is not considered to be unreasonable or detrimental to the study participants.  The risk will be 
appropriately managed with a combination of modern real time CGM, close supervision by [CONTACT_474825], and appropriate education of study participants. 
Results from pre-clinical animal and bench studies of the Capi[INVESTIGATOR_704463] a lower rate of cannula kinking (0% vs 57% in an equivalent commercial infusion set, p<0.001) 
and improved infusion set functionality for extended use periods beyond 3 days. These pre-clinical data 
further demonstrate that kinking is much less likely using the Silhouette set as compared to the QuickSet 
in humans.  This finding suggests that early failure with the Silhoutte should be much lower than that 
observed in the Patel study.  This finding in swine mirrors anecdotal reports from clinical practice and 
again suggests that the failure rate quoted in the Patel study overstate the expected outcome in the 
control arm of the proposed study, correspondingly reducing overall risks to participants. 
This study is designed to evaluate if similar results can be reproduced in human participants using 
routine insulin pump therapy for two extended use (up to 7 days) use wear periods of the Achilles 
infusion set.  Participants will frequently monitor their blood glucose levels to ensure adequate glycemic 
control. Infusion set change out for any reason will be performed per standard therapy with no 
additional risk to the study participant or ongoing therapy.  
[ADDRESS_957278] of insulin from DOI through day 7 (0, 3, 5, and [ADDRESS_957279] insertion) compared to 
the commercially available control.  .   
3.2 SECONDARY OBJECTIVES 
1.To assess other pharmacodynamics (PD) parameters of insulin within and across treatments
following subcutaneous delivery using Achilles vs Teflon control set on DOI (day 0) and days 3, 5,
and [ADDRESS_957280] insertion
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 24 2.To assess pharmacokinetic (PK) parameters within and across treatments following
subcutaneous insulin delivery using Achilles vs Teflon control set on DOI and days 3, [ADDRESS_957281]
insertion.
3.To assess continuous glucose monitoring (CGM) data, comparing data within and across
treatments.
4.To assess performance of investigational infusion set on DOI (day 0) through +7 (8th calendar day
of wear) for each treatment
3.3 SAFETY OBJECTIVES 
To assess safety and tolerability of investigational infusion set on DOI through day +[ADDRESS_957282] insertion (8th 
calendar day of wear) for each treatment as measured by [CONTACT_704498]. 
[ADDRESS_957283] randomized, cross-over trial investigating the survivability, 
consistency, efficacy, and safety of an extended wear time investigational insulin infusion set (CapBio 
Achilles). This is achieved by [CONTACT_704499] a bolus of rapid acting insulin on 4 separate 
days of CSII set wear time during 2 separate wear periods in up to 30 adult patients with T1DM.  
4.1.2  ACHILLES INFUSION SET DEVICE DESCRIPTION 
The Achilles infusion set is a sterile, non-pyrogenic, single use device for continuous subcutaneous 
insulin infusion (CSII). Achilles infusion sets are designed to be used with commercially available infusion 
pumps (e.g., Medtronic MiniMed). The use of the Achilles infusion set is identical to the commercially 
available MiniMed Silhouette control device (see reference document 710-1021-00 Achilles infusion set, 
Instructions For Clinical Use). The investigational Achilles infusion set differs from the commercial 
Silhouette device only in the materials (coil-reinforced soft polymer vs. Teflon) and construction (three 
side ports vs. single distal port) of the indwelling cannula. 
Each infusion set has two basic components: the infusion set body with an indwelling cannula and a 
tubing set for connection to the infusion pump reservoir. The Achilles infusion set body is provided 
individually packaged. The infusion set body is then connected to the tubing set from a commercially 
available infusion set with the proprietary pump reservoir connector (e.g., Medtronic Paradigm) for use 
with specific infusion pumps. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 25 Figure 2: Achilles Infusion Set 
4.1.2  INDICATION/INTENDED USE 
The Achilles infusion set is intended for the subcutaneous infusion of medication, including insulin, from 
an external infusion pump. 
4.1.3  CAUTIONS, WARNINGS AND PRECAUTIONS 
CAUTION 
Investigational device. Limited by [CONTACT_120906]. 
WARNINGS 
The Achilles infusion set is only sterile and non-pyrogenic if the packaging is unopened and undamaged. Do not use 
it if the packaging is already opened or is damaged. 
Go through instructions for use carefully before inserting Achilles, as failure to follow instructions may result in 
pain or injury. 
Inaccurate medication delivery, infection and/or site irritation may result from improper insertion and 
maintenance of infusion site. 
When using Achilles for the first time, do so in the presence of a healthcare provider. 
Achilles is a single-use item, which must be disposed of after usage. Do not clean or re-sterilize. 
Be sure that the needle guard is removed before insertion. 
People with small or large amounts of subcutaneous fat should choose the insertion angle carefully, as the cannula 
could be placed in underlying muscle or dermal layer and thus reduce or block medication delivery. Normal 
insertion angle is between 30 - 45°. Consult your healthcare provider concerning this matter. 
Do not leave air in the infusion set. Make sure to fill Achilles completely. 
Do not put disinfectants, perfumes, deodorants or other products containing alcohol or disinfectants in contact 
[CONTACT_704500], as these may affect the integrity of the infusion set. 
Replace the infusion set if the adhesive tape becomes loose. 
Check the infusion set frequently to ensure that the soft cannula remains firmly in place. Replace if it is not 
secured. Since the cannula is soft, it will not cause any pain if the soft cannula becomes fully or partially dislodged 
from the skin, and this may take place without notice. The soft cannula must always be completely inserted to 
receive the full amount of medication. 

Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957284] the infusion set per your healthcare provider’s instructions.  
If the infusion site becomes inflamed, replace the set and use a new site until the first site has healed. 
Do not re-insert the introducer needle into the infusion set. Re-insertion could cause tearing of the soft cannula, 
which would result in unpredictable medication flow. 
Never prime the infusion set or attempt to free a clogged tubing while the set is inserted. You may accidentally 
inject too much medication. 
Use aseptic techniques when temporarily disconnecting Achilles, and seal the cannula housing with the cover 
provided. Consult with the healthcare provider on how to compensate for missed medication when disconnected. 
Protect Achilles from direct sunlight. Store at room temperature. 
Reuse of the infusion set may cause infection, site irritation, or damage to the cannula/needle. A damaged 
cannula/needle may lead to inaccurate medication delivery. 
When infusing insulin, carefully monitor BG levels when disconnected and after reconnecting. 
When infusing insulin, and BG level becomes unexplainably high, or occlusion alarm occurs, check for clogs and 
leaks. If in doubt, change the infusion set since the soft cannula could be dislodged, crimped or partially clogged. 
Discuss a plan for rapid replacement of insulin with the healthcare provider should any of these problems arise. 
Test BG level to make sure the problem is corrected. 
When infusing insulin, check the BG level 1-[ADDRESS_957285] between treatment periods and to 
allow the study participants to recover from blood loss associated with clamp procedures.     
4.3 JUSTIFICATION FOR DO SE 
A bolus of commercial U-100 insulin lispro (0.15 units/kg) will be infused through an investigational or 
commercial infusion set into the SC tissue of the abdomen at time zero (t0 on DOI and on Days 3,5 and 
7) of each glucose clamp PK/PD study using a Medtronic pump. The concentration of BG will be
maintained approximately in the 95±15 mg/dL range using an IV infusion of 20% dextrose and/or insulin
infusion.. The IV dose may range from 0.1 to 3.0 units/h depending on the patient’s regular basal rate.
This insulin lispro bolus dose (0.15 units/kg) is slightly higher than a typi[INVESTIGATOR_704464] a T1DM patient with an average insulin/carbohydrate ratio 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 27 (0.15 units/kg x 70 kg = 10.5 units). The majority of the published PK/PD studies utilized a 0.15 unit/kg 
bolus dose, some used a 0.20 units/kg bolus dose, and a few studies used a 0.10 or 0.12 unit/kg dose.   
Insulin lispro will be infused through the same investigational or commercial insulin infusion set after 
each glucose clamp (or until CSII failure) using a Medtronic insulin pump and a basal/bolus pattern of 
delivery. The basal infusion rate, meal bolus dose and correction dose will be adjusted by [CONTACT_704501] [SMBG glucose measurements, CGM glucose 
measurement (if available), insulin to carbohydrate ratio, meal size and meal composition]. Study 
participants requiring a large daily insulin dose may require a change out of their pump reservoir with 
fresh insulin as needed during each treatment period.       
4.[ADDRESS_957286] scheduled procedure shown in Section 1.3 and Figure 1. 
5 STUDY POPULATION 
5.1 INFORMED CONSENT 
An informed consent, written in accordance with the Declaration of Helsinki will be obtained from each 
participant before commencing any trial-related activities. The person/physician responsible for 
recruitment will explain the nature, purpose and potential risks of the study and will provide the 
participant with a copy of the signed informed consent.  
5.[ADDRESS_957287] meet all of the following criteria: 
1.Participants are 18 – [ADDRESS_957288] be geographically stable (e.g., expects to be available and capable of returning
for all study specified test and examinations) during the study period
5.Participant has been diagnosed with T1DM for at least 12 months
6. C-peptide <0.6 nmol/L at screening
7.Participant has been using insulin pump therapy for at least 6 months and is currently using a
Medtronic MiniMed pump, model series 530 or higher.  Use of 670G in auto mode is acceptable.
8. Participant can provide a minimum of 14 days of insulin pump data to demonstrate pump use
compliance
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 28 9. Participant is willing to perform frequent (4 times per day or more) self-monitoring of blood
glucose (SMBG), including before meals and before bed, and using a meter and test strips
provided by [CONTACT_704502].  This includes participants
who are currently using real-time continuous glucose monitoring and may continue to do so, but
must also collect SMBG values as instructed.
10. Participant is willing to perform serum ketone measurements whenever the blood glucose is
determined to be greater than 250 mg/dL after extended fasting (e.g. overnight or more than
five hours after a meal) using a ketone meter and strips provided by [CONTACT_456]
11.Participant has BMI in the range 20 – 35 kg/m2 inclusive
12.Participant has experience infusing a rapid-acting insulin analog for at least 6 months
13.Participant has been using or is willing to use CGM (reading data available for at least 80% of
time for a week of data collection during the screening period).  Participants already using
Dexcom G6 real time CGM may continue to use their own CGM unit; participants not using the
G6 will be provided with a G6 monitor.  All participants will be provided with CGM disposables
for use during the treatment period.
14.Participant has ability to understand and comply with protocol procedures and to provide
informed consent
15.HbA1c ≤8.5%
16.Stable body weight in the 3 months prior to enrollment (change in body weight <5%)
5.3 EXCLUSION CRITERIA 
An individual who meets any of the following criteria will be excluded from participation in this study: 
1)Participants whose average total daily insulin dose exceeds 85 units/day (i.e. typi[INVESTIGATOR_704465] 4 days on average)
2)Participants who routinely change their commercial insulin infusion sets on average less often
than every 4.5 days1
3)Female participant is pregnant or nursing2
4)Participant has abnormal skin at intended device infusion sites (existing infection, inflammation,
burns, or other extensive scarring)
5)Participant has hemoglobin <12.0 g/dL or  potassium < 3.5 mEq/L at screening
1 This will be determined during screening by [CONTACT_704503]’s Medtronic pump. The pump data 
includes date and time of “cannula prime” events which can be used as surrogate for infusion set  change time. 
[ADDRESS_957289] results for female participants required unless participant is menopausal 
without any spontaneous menstrual cycles for >[ADDRESS_957290] been removed. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 29 6)Participant has documented history in last [ADDRESS_957291] party intervention or a history of
impaired awareness of hypoglycemia.
7)Participant has a history of diabetic ketoacidosis in the last 6 months
8)Participant has known cardiovascular disease considered to be clinically relevant by [CONTACT_31035]
9)Participant has known arrhythmias considered to be clinically relevant by [CONTACT_093]
10)Participant has known history of:
a)Cushing’s Disease,
b)pancreatic islet cell tumor, or
c)insulinoma
11)Participant has:
a)Lipodystrophy,
b)extensive lipohypertrophy, as assessed by [CONTACT_093]
12)Participant is undergoing current treatment with:
a)Systemic oral or intravenous corticosteroids,
b)monoamine oxidase (MAO) inhibitors,
c)non-selective systemic beta-blockers,
d)growth hormone,
e)thyroid hormones, unless use has been stable during the past 3 months
f)SGLT2 inhibitors
13)Participant has significant history of any of the following, that in the opi[INVESTIGATOR_704466]’s safety or successful study participation:
a)Alcoholism,
b)drug abuse
14)Significant acute or chronic illness, that in the investigator’s opi[INVESTIGATOR_1649], might interfere with
participant safety or integrity of study results
15)Planned operation, MRI or CT which require removal of infusion set or CGM sensor during wear
periods
16)Current treatment with systemic (oral or IV) corticosteroids, monoamine oxidase (MAO)
inhibitors, non-selective beta-blockers, growth hormone, herbal products that, in the opi[INVESTIGATOR_277392], may alter insulin sensitivity or confer undue risk to the participant’s
participation in the study or n on-routine vitamins. Furthermore, thyroid hormones are not
allowed unless the use of these has been stable during the past 3 months.
17)Current participation in another clinical drug or device study
18)Inability of the participant to comply with all study procedures or to understand the participant
instructions
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957292] 24 hours prior to dosing
2.Any medical condition which, in the opi[INVESTIGATOR_704467]/or
glucose metabolism
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 31 5.5 LIFESTYLE CONSIDERATIONS 
During this study, participants are asked to: 
Refrain from use of analgesics 12 hours prior to pain assessment
Abstain from alcohol for 24 hours before the start of each clamp
Refrain from strenuous exercise 24 hours before each clamp
Refrain from eating a high-carb meal (e.g. Pi[INVESTIGATOR_6107]) before admission to the study center
Keep a diabetes diary provided by [CONTACT_5984]
Wear a CGM during each 7 day study period provided by [CONTACT_5984] (Dexcom G6®)
5.6 SCREEN FAILURES 
Patients who fail screening due to hemoglobin <12.0 g/dL and  potassium < 3.5 mq/L eligibility criteria 
may be rescreened 1 time up to 2 weeks later.   
 The site may rescreen one time for A1C >8.5% and/or C-peptide. ≥0.6 nmol/L up to [ADDRESS_957293] had experience with frequent CSII set change outs or who desire to contribute to the 
evaluation of an extended CSII set will be given the opportunity to participate in the Achilles extended 
wear feasibility study. This study has been designed as a short (< 30 day) period trial and should not 
interfere with patient’s usual routine, work or social life. Clinical visits and study requirements have 
been minimized so as to not interfere with daily activities. 
Recruitment materials may include written, broadcast and/or internet advertising to facilitate broad 
patient participation. All recruitment materials shall be submitted to the IRB for review prior to use. 
Participants will receive a study stipend for study participation and will be prorated based upon the 
number of clamps they complete. 
6 STUDY INTERVENTION 
6.1 STUDY INTERVENTION ADMINISTRATION 
6.1.1  STUDY INTERVENTION DESCRIPTION 
[IP_ADDRESS]  POINT OF ENROLLMENT 
Potential patients will be screened for study participation based on the eligibility criteria given in Section 
5.1 above. After completing written informed consent, eligible participants shall be assigned a unique 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 32 study identifier. Eligible participants will be considered “enrolled” once they signed the informed 
consent form.  
[IP_ADDRESS] SCREENING AND BASELINE (DAY -21 TO DAY -1, VISIT 0) 
Participants will be screened and tested to verify study eligibility criteria including a physical exam, 
complete medical history and laboratory testing. Female participants of child-bearing age, who do not 
have a documented history of menopause (defined as at least 12 months without menses and/or 
removal of key organs) must undergo a urine pregnancy test within [ADDRESS_957294] also undergo a urine drug/alcohol screen test, complete blood and metabolic 
panels within the required screening period (Table 5 ). 
Patients who fail screening due to hemoglobin <12.0 g/dL and potassium <3.5 mq/L eligibility
criteria may be rescreened for study eligibility 1 time up to 2 weeks later.
Patients who fail the drug/alcohol screening test may be rescreened for study eligibility one (1)
time up to 2 weeks later.
If participants are not currently using and/or are not familiar with the Dexcom G6® CGM sensor, study 
staff will insert the study sensor during the screening visit and are asked to familiarize themselves with 
the sensor for 7 days. After one week, CGM data will be downloaded and assessed. If CGM data shows 
readings for approximately 80% of sensor wear time, the participant may be enrolled in the study. If 
readings are less than 80%, the participant will be given another week of training. If after the second 
training period, the threshold of 80% is still not met, the participant is not eligible to participate in the 
trial.  
Participants will be provided with diabetes diaries and a bag of material (see [IP_ADDRESS]) for times spent at 
home in between study visits to the CRU.  Participants will be reminded to fast 12 hours prior to Visit 1 
and to avoid a high-carb dinner (e.g. pi[INVESTIGATOR_6107]). They are furthermore instructed to refrain from strenuous 
exercise and alcohol during the 24 hours preceding Visit 1.  
Table 5: Screening and Baseline Required Exams  
Requirement  Comments  
Inclusion criteria  Ensure patients meets all of the inclusion and none of the 
exclusion criteria  
Informed consent  Written consent required by [CONTACT_704504], gender, race, ethnicity 
Medical history  All co -morbidities, prior interventions, Indication for 
Treatment  
Urine Pregnancy test  Female participants of child -bearing potential who are not 
documented post -menopausal or have undergone 
extirpation of key organs  
Urine Drug/Alcohol Screening  Participants who test positive for drug/alcohol at screening 
are excluded from s tudy participation. Participants may 
retest one (1) time within [ADDRESS_957295] T1DM as defined in eligibility 
criteria are excluded 
HbA1C  Participants with Hb1AC>8.5% are excluded from study 
Basic Metabolic Panel  Sodium, Potassium, Bi -carbonate (also known as carbon 
dioxide, or CO2), Chloride, BUN, Serum Creatinine  
*Potassium <3.5  mg/L are excluded
ECG 12 lead ECG required 
Participant Training Insertion site visual inspection, Achilles infusion set change -
out, and  device return instructions  
Study CGM  Insertion and training as needed  
Personal CGM  Optional use; if used record Model/Serial number  
[IP_ADDRESS] RANDOMIZATION 
Participants will be randomized at Visit 1 1:[ADDRESS_957296] as their own control and minimizes user bias. (See section 1.2 for 
schema.) 
After an overnight stay and glucose stabilization, glucose clamp PK/PD experiments will be performed 
on a Friday, Monday, Wednesday, and Friday schedule, followed by a 2±1 week wash-out period, 
followed by a second week of glucose clamp PK/PD experiments on a Friday, Monday, Wednesday, and 
Friday schedule. Alternate days of the week scheduling maybe employed as needed to meet participant 
and research unit flexibility. 
[IP_ADDRESS] OVERNIGHT STABILIZATION 
Participants arrive at the clinical site the evening prior to clamp experiment study visits. Site may 
provide dinner. Participant eligibility will be rechecked (Section 5.4) and those participants eligible to 
participate will stay onsite overnight. Two intravenous (IV) catheters will be inserted into a peripheral 
vein, one in each hand/arm: one for blood sample acquisition and one for the infusion of 
dextrose/insulin. To target a glucose level around 85-115 mg/dL the following morning, participants may 
be administered insulin at the investigator’s discretion by [CONTACT_704505] U100 insulin dissolved in 
saline. Once the IV insulin has been initiated, the participant’s  insulin pump will be set at a basal rate of 
0.1 U/h overnight and throughout the clamp procedure the next day.  The concentration of plasma 
glucose will be determined using a reference analyzer (YSI 2300 Plus) and also by [CONTACT_704506]/test 
strips per investigator’s discretion. If BG is low, IV infusion of  dextrose may be necessary.  
A commercial CGM (Dexcom G6) will be inserted into the SC tissue of each study participant using 
aseptic technique to record the interstitial fluid glucose concentration. The CGM device will be removed 
by [CONTACT_704507] (or sooner if cannula failure has occurred prior to Day 7) 
during each of the 2 treatment periods. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 34 Food will be withheld (NPO except for water and glucose tablets as needed) for [ADDRESS_957297] the following morning. 
[IP_ADDRESS] VISIT 1 (FRIDAY) 
In the morning, a new infusion set (experimental or control) will be inserted by [CONTACT_3462], the 
infusion site will be photographed, and the glucose clamp procedure will be initiated.   
The hand/arm used for blood sample acquisition will be gently warmed using a heating pad to produce 
“arterialized” blood samples.  Failure to sample blood from an IV catheter may require insertion of one 
or more additional IV catheters to complete each 5-hour clamp study.   
The reservoir of the insulin pump will be filled with insulin lispro. The reservoir of the participant’s pump 
will be removed and replaced with the insulin prepared by [CONTACT_44518]. The 23" insulin tubing 
will be connected to the pump and primed. The infusion set plastic hub will be over-taped with Simpatch 
kinesthesiology tape to further ensure that cannula dislodgement will be unlikely during the treatment 
period.  Areas of lipohypertrophy/lipodystrophy and areas of recent CSII insertion will be avoided. The 
participant’s own commercial infusion set will be removed, and a  commercial/investigational cannula 
will be inserted at an angle of approximately 30 degrees into the subcutaneous tissue of the abdomen 
using aseptic technique, approximately 3 cm lateral to the midline and, following a cannula prime 
procedure. The pump immediately started on a constant basal rate of 0.1 U/h which will be maintained 
throughout the clamp. There should be a suitable insertion site on the contralateral abdomen at 
approximately the same rostral/caudal level to be used during the second treatment period.  
The run-in period should last no longer than 3 .5 hours, if BG is not stable after this time, the participant 
cannot continue in the study and is sent home. He/she may return another day. Once the BG level of 
approximately 95±15 mg/dL has been maintained for at least 40 minutes (measured every 10 minutes), 
the IV insulin (dextrose) is discontinued, and the baseline will be recorded for 20 min (blood draw every 
5 min). 20 minutes after discontinuation of IV insulin, a SC bolus of lispro insulin (0.15 U/kg) is 
administered via the pump (t0). Baseline plasma glucose level is defined as mean plasma glucose at time 
points t-20, t-15, t-10, t-5, and t0. After t0, blood samples for PK analysis are drawn every 3 minutes for 
15 min (Clamp Part I), every 5 minutes for 40 minutes (Clamp Part II), every 10 min for 30 min (Clam p 
Part III), and every 15 minutes for 45 minutes. In the Final Phase, blood is drawn every half an hour until 
clamp termination at 300 minutes (see Table 6). Up to [ADDRESS_957298]-
bolus.  Blood samples will be acquired using aseptic technique and double stopcock technique to 
minimize blood loss. A maximum of 66 samples (24 x 1.5 mL [for BG and insulin] + 6 x 1.0 mL [for PK 
only] + 36 x 0.5 mL for BG only = 62.0 mL] will be drawn during the stabilization period and the clamp 
procedure, resulting in a total blood loss of 248 mL during 4 clamps over each week. Combining both 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 35 clampi[INVESTIGATOR_704468], this represents less than 1 unit of blood (=525 mL). Blood samples will be centrifuged 
to plasma, plasma glucose concentration measured, and plasma frozen in 2 aliquots for future 
measurement of insulin concentration.  The detailed clamp sampling schedule is summarized in Table 6. 
Table 6. Clamp visit sampling schedule 
Phase Approximate Clock 
Time (hh:mm)  Nominal 
Time (min)  No. of 
samples Volume/Sample (mL)  Total 
Volume 
(mL)  
Stabilization, over night  15 0.5 7.5 
Baseline Part I  7:00  -60
5 0.5 
2.5 7:10  -50 0.5 
7:20  -40 0.5 
7:30  -30 0.5 
7:40  -20 0.5 
Discontinue IV insulin & Dextrose  
Baseline Part II  7:45  -15
3 1.5 
4.5 7:50  -10 1.5 
7:55  -5 1.5 
Bolus  8:00  0 1 1.5 1.5 
Clamp Part I  8:03  3 
7 1 
6.5 8:05  5 0.5 
8:06  6 1 
8:09  9 1 
8:10  10 0.5 
8:12  12 1 
8:15  15 1.5 
Clamp Part II  8:20  20 
9 1.5 
13.5  8:25  25 1.5 
8:30  30 1.5 
8:35  35 1.5 
8:40  40 1.5 
8:45  45 1.5 
8:50  50 1.5 
8:55  55 1.5 
9:00  60 1.5 
Clamp Part III  9:10  70 
3 1.5 
4.5 9:20  80 1.5 
9:30  90 1.5 
9:40  100 0.5 
Clamp Part IV  9:45  105 10 1 8.0 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 36 Phase Approximate Clock 
Time (hh:mm)  Nominal 
Time (min)  No. of 
samples Volume/Sample (mL)  Total 
Volume 
(mL)  
9:50  110 0.5 
10:00  120 1.5 
10:10  130 0.5 
10:15  135 1 
10:20  140 0.5 
10:30  150 1.5 
10:40  160 0.5 
10:50  170 0.5 
Final Phase  11:00  180 
13 1.5 
11.5  11:10  190 0.5 
11:20  200 0.5 
11:30  210 1.5 
11:40  220 0.5 
11:50  230 0.5 
12:00  240 1.5 
12:10  250 0.5 
12:20  260 0.5 
12:30  270 1.5 
12:40  280 0.5 
12:50  290 0.5 
13:00  300 1.5 
Observation at site  66 total 
samples  
Total volume per clamp =  62.0 mL  
During the 5-hour clamp plasma glucose concentration will be maintained at 95±15 mg/dL with IV 
infusion of dextrose (0.1 to 4 mg/kg/min), titrated using a computerized dosing algorithm according to 
frequent BG measurements. The trigger plasma glucose concentration for onset of glucose infusion will 
be a value that is 5 mg/dL below the mean obtained during Baseline Part II (i.e. -15, -10 and -5 minutes 
before bolus delivery at T=0). The dosing calculator will be used to determine the optimal glucose 
infusion rate (GIR) for each subsequent time period between BG measurements. If insulin is infused, 
glucose infusion must be stopped and vice versa. The dextrose infusion rate will be increased to match 
insulin lispro’s glucose lowering effect over time until the glucose lowering effect of the insulin lispro 
bolus reaches baseline (i.e. glucose infusion rate of 0) or 5 hours after bolus administration.  
In the case of persistent hyperglycemia (BG>250 mg/dL) over 30 minutes without dextrose infusion, the 
clamp will be terminated early. A correction bolus will be given via the pump and the BG measured to 
determine whether BG was lowered by 50 mg/dL within [ADDRESS_957299] finished their meal and their BG has dropped as assessed by 
[CONTACT_704508] 90 – 200 mg/dL separated by [CONTACT_2669] 30 
minutes. 
The study participant will be provided with a meal at the conclusion of the clamp visit.  Insulin lispro will 
be infused through the study investigational or commercial CSII catheter usi ng the participant’s typi[INVESTIGATOR_704469]/bolus pattern of delivery during home care between study visits. Study personnel will call the 
participant the same evening to ensure the participant’s wellbeing.  
[IP_ADDRESS]  VISITS 2, 3, AND 4 
Participants arrive the prio r evening for stabilization and procedures explained above in section “Visit 1” 
are repeated (except insertion of CSII catheters). If CGM failed, a new CGM will be inserted by [CONTACT_152718].  
If the CSII catheter does not fail before day 7, the investigational/commercial CSII set will be removed 
upon completion of the clamp experiment on Visit 4A/Visit 4B. The site and cannula will be 
photographed,  and the cannula inspected under a microscope. A fresh CSII catheter (as routinely used 
by [CONTACT_2299]) will be inserted at a different site, the pump connected, and routine glycemic 
management resumed. The change-out will be documented in the appropriate source documents and 
CRF. 
[IP_ADDRESS]  HOME CSII TREATMENT PHASE 
During the home CSII treatment phase participants will use the investigational/control CSII catheter in 
combination with the Medtronic MiniMed insulin pump for diabetes management. Participants will 
follow their regular lifestyle, adjusting basal infusion rate, meal bolus doses and correction doses 
according to their routine clinical methods. They will use their diabetes diaries to document VAS pain 
score, signs/symptoms of hypoglycemia, treatment of hypoglycemia, CSII catheter issues, and overall 
health. BG will be measured continuously by [CONTACT_540458].  
Study participants will receive detailed instructions regarding diabetes care plan, including dietary 
guidelines, treatment of hyperglycemia, hypoglycemia, and the management of CSII catheter failure. 
Participants will be instructed to monitor their blood ketone levels if their CGM or SMBG values are 
greater than 250 mg/dL for more than 2 hours or they develop signs/symptoms of diabetic ketoacidosis.  
Table 7: Participant instruction for at home use 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 38 [IP_ADDRESS]  STUDY TESTING COMPLETION 
Discontinuation from the study intervention (infusion of insulin through a CSII catheter) does not mean 
discontinuation from the study, and remaining study procedures should be completed as indicated by 
[CONTACT_4690]. The need to discontinue clinical use of the investigational or commercial CSII 
catheter prior to Visit 4A/Visit 4B is expected in some study participants and is not considered an 
adverse event.  If an unplanned change-out of either the Achilles investigational cannula or control CSII 
set is required during a study visit/clamp, participant’s study participation in the resp ective treatment 
phase is considered completed at the time of infusion set change. If change-out occurs during Treatment 
Phase [ADDRESS_957300] be 
completed: 
Inspect/photograph insertion site
Collect patient diary/photos
After completion of final evaluations, participant may be exited from the study. 
[IP_ADDRESS]  ANCILLARY PRODUCTS AND ACCESSORIES 
During Visit 0, Participants will be provided with diabetes diaries and a bag of material for times spent at 
home in between study visits to the CRU.   
Contents of bag: 
Achilles infusion set change out and device return instructions
Glucose meter (handling is explained by [CONTACT_464])
Ketone meter (handling is explained by [CONTACT_464])
Glucose strips
Ketone strips
Glucose tabs
DiaryPatient Diary (daily)  Participant records:  
Hypo -/hyperglycemic epi[INVESTIGATOR_1841]
Insertion site assessments
Insertion set failure
Other device issues or complications
VAS Pain Scale (daily insertion site comfort levels)
Insertion Site Assessment (daily)  Participant visually inspects and records insertion site 
findings (i.e. skin reaction or infection)  
Dexcom G6® CGM  Records glucose values throughout study  
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 39 Cap for infusion set (in case of failure)
Ruler/Cutout to measure erythema
Container & biohazard bag for CSII catheter (in case of failure)
Alcohol swabs
Study sponsor shall provide the following study materials and products for study use only: 
Dexcom G6® CGM
Fast-acting insulin (Insulin Lispro U100/Humalog)
oNOTE:  Participants who are using other pump insulins will be switched to lispro after
screening and  informed consent to participate have been completed.
6.1.9 STUDY VISIT WINDOWS 
Study visits are scheduled as indicated above; however, it is recognized that study participants may not 
be able to return for scheduled visits at precisely the date required. Therefore, study visit windows have 
has been defined for each visit per Table 8 below. 
Table 8: Schedule of Follow-Up Visits and Visit Windows 
Visit Visit Window  
Screening/Baseline -28 to -1 days
Wear Period DOI to +7 days inclusive 
Study Completion  8th calendar day or upon infusion set failure  
Follow -up Patients will receive follow -up phone call by 
[CONTACT_3655] 1 day after each period 
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY 
Sterile study devices (Achilles infusion sets) shall be provided by [CONTACT_704509] a cool, dry, 
secure location at each study site. Insulin lispro shall be stored and dispensed per site requirements. 
Study BG and ketone monitors, test strips and study CGMs shall be stored per the labeling. All ancillary 
study products will be labeled and distributed to the sites to be provided to each study participant on 
Day of Insertion (Day 0). All study device and drug inventory must be returned to the study center or 
pharmacy before the participant officially exits the study. 
6.2.1  FORMULATION, APPEARANCE, PACKAGING, AND LABELING 
Achilles infusion sets come packaged sterile and single use only in a Tyvek pouch. Sufficient quantities of 
investigational infusion sets will be provided to the study center prior to study start. Replacement 
and/or additional units shall be provided upon site request to Sponsor. 
Insulin lispro will be provided per standard packaging and labeling by [CONTACT_704510]. Insulin will be dispensed per the study protocol and only for the study duration to any eligible 
study participant. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 40 6.2.2  PREPARATION 
Achilles infusion sets shall be prepared and applied to the participant as described in reference 
document “ 710-1021-00 Achilles infusion set, Instructions for Clinical Use ”. For this 7-day study, 23” (60 
cm) tubing from commercially-available MiniMed Silhouette infusion sets shall be used.
The infusion set hub shall be secured to the body with a kinesiology tape over-bandage. If the 
participant routinely under-bandages or over-bandages using other dressings with their normal infusion 
set they should continue to do so when using the Achilles infusion set.   
Insulin lispro, infusion pump, BG and ketone monitors and study CGM shall be prepared per the 
applicable product instructions for use. IV insulin will be prepared by [CONTACT_704511]. Insulin reservoirs are filled with insulin lispro and inserted into the participant’s pump on 
Visit 1 or other clamp days (dependin g on the participant’s insulin requirements, [ADDRESS_957301] the 
entire treatment period or less). 
6.2.3  ACHILLES INFUSION SET DEVICE ACCOUNTABILITY 
The Sponsor shall keep records to document the physical location of all investigational devices from 
shipment of investigational devices to the investigation sites until return or disposal. The principal 
investigator [INVESTIGATOR_5694], use, return and 
disposal of the investigational devices, which shall include the date of device receipt, investigational 
device identification (batch, serial or unique study ID code), expi[INVESTIGATOR_656519], date or date(s) of 
use, related participant study ID, data device was returned/removed from participant, date of return of 
unused or expi[INVESTIGATOR_704470]. Product accountability returns and/or exchanges shall be 
documented per Sponsor standard operating procedures and investigational product release and return 
procedures. 
Ancillary products shall be labeled with th e participant’s study ID number. Records of study provided 
glucose and blood ketone monitors and CGM will be tracked as required above. Insulin will be dispensed 
per pharmacy standard operating procedures to study participants only. 
6.3 MEASURES TO MINIMIZE BIAS 
Participant treatment will be assigned in a randomized sequence to avoid sequence bias. A washout 
period of 2+[ADDRESS_957302] be 
completed and CGM data will serve as electronic source documentation for hyperglycemic and 
hypoglycemic adverse events. Additionally, inquiries documented in clinic notes will be used for source 
documentation of patient-reported AEs. Photographs of infusion site will serve as source documentation 
for infusion site reactions.  
The following will be collected regularly and documented: 
Study participan t’s insulin pump records
Interstitial fluid glucose data from Dexcom G6® CGM throughout each study period (assessed by
[CONTACT_102870])
BG measurements per Bayer Contour NEXT device will be used by [CONTACT_704512].  Data will be downloaded at each clinic visit
Serum ketones - measured by [CONTACT_704513] (in case of hyperglycemia
occurring during fasting or acute illness)
Study participant diary (Pain score, SMBG)
6.[ADDRESS_957303] of care rescue medicine will be allowed to treat: 
Transient hyperglycemia (insulin using commercial CSII cannula)
Transient hypoglycemia (juice or glucose tabs or, as needed, glucagon or IV glucose)
7 DISCONTINUATION AND WITHDRAWAL 
7.1 DISCONTINUATION OF STUDY INTERVENTION 
 7.1.1 INFUSION SET CHANGE-OUT/EARLY DROPOUT 
Independent of the time point for infusion set removal/change out, study staff is to follow the SOP for 
Infusion Set Removal and the reason for change-out is to be documented in the applicable source 
document and CRF. 
We anticipate several commercial and/or investigational CSII catheters to fail prior to the fourth glucose 
clamp experiment on day 7.  Participants will be instructed to contact [CONTACT_704514] (24/7) to confirm the diagnosis of a failed CSII catheter. If the CSII catheter does not fail 
before day 7, the investigational/commercial CSII set will be removed upon completion of the clamp 
experiment on Visit 4A/Visit 4B. The site and cannula will be photographed, and the cannula inspected 
under a microscope. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F 
Confidential Uncontrolled when printed 42 The following are objective criteria that define a CSII catheter/infusion set failure: 
1.The occurrence hyperglycemia (glucose >250 mg/dL) not responsive to a pump bolus dose
where response to the bolus is defined as a fall of at least 50 mg/dL in blood glucose within one
hour.
2.The occurrence of hyperglycemia (glucose >250 mg/dL) after prolonged fasting (e.g. overnight or
more than 5 hours following a meal), not associated with acute intercurrent illness, but with a
concurrent ketone level ≥0.6 mmol/L.
3.Signs of inflammation/infection at the infusion site including pain, erythema or induration >10
mm in diameter.
4.Occurrence of an insulin pump occlusion alarm signal.
In the case that any of the above occurs during home-use, the participant is asked to call the 24/7 
helpline and confirm catheter failure with the study staff. The study participant will insert a new 
commercial CSII catheter (as used routinely by [CONTACT_508386]) into the subcutaneous tissue at an alternate 
location and connect it to the insulin pump for routine glycemic management. The failed CSII catheter 
will be left in place. The participant is asked to measure erythema around the catheter and photograph 
the site. The study participant will return to the study site as soon as practicable so the research staff 
can remove and observe the failed CSII catheter. Study staff is to follow the SOP for catheter removal.  
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY 
Participants are free to withdraw from participation in the study at any time upon request. An 
investigator may discontinue or withdraw a participant from the study for the following reasons: 
Severe hyperglycemia or ketoacidosis during the study
Adhesive allergy/intolerance developed during the study
Any condition or change in condition compromising the safety of the participant as judged by
[CONTACT_978] [INVESTIGATOR_704471]
Pregnancy.
Significant study intervention non-compliance.
If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation
occurs such that continued participation in the study would not be in the best interest of the
participant.
If the participant meets an exclusion criterion (either newly developed or not previously
recognized) that precludes further study participation.
Study participant unable to participate in the second series of glucose clamp experiments after
2±1 week wash-out period.
DKA, characterized by [CONTACT_704515] (serum ketones elevated to >1.5 mmol/L) and
metabolic acidosis with depressed serum bicarbonate level to less than 18 mmol/L and/or
arterial pH less than 7.30.
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 43 The reason for participant discontinuation or withdrawal from the study will be recorded on the CRF. 
Participants who sign the informed consent form and are randomized but do not receive the study 
intervention (placement of the first CSII catheter) may be replaced. Participants who sign the informed 
consent form, and are randomized and receive the study intervention, and subsequently withdraw, or 
are withdrawn or discontinued from the study, will not be replaced. 
7.[ADDRESS_957304] be taken if a participant fails to return to the clinic for a required study visit: 
The site will attempt to contact [CONTACT_62541] a day and
counsel the participant on the importance of maintaining the assigned visit schedule and
ascertain if the participant wishes to and/or should continue in the study.  Instructions shall be
provided to the participant on returning to the site for EOS assessments and product return, if
the participant decides to withdraw from the study.
Before a participant is deemed lost to follow-up, the investigator or designee will make every
effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary,
a certified letter to the participant’s last known mailing address or local equivalent methods).
These contact [CONTACT_13140]’s medical record or study file.
Should the participant continue to be unreachable, he or she will be considered to have
withdrawn from the study with a primary reason of lost to follow- up.
8 STUDY ASSESSMENTS AND PROCEDURES 
8.1 EFFICACY ASSESSMENTS 
Multiple samples will be taken during each clamp procedure and plasma insulin levels will be analyzed 
using insulin assays. 
8.2 SAFETY AND OTHER ASSESSMENTS 
The following labs and procedures will be conducted to ensure patient safety: 
Physical examination  (e.g., height and weight, organ systems, motor or vision assessment, or
other functional abilities). If appropriate, discuss what constitutes a targeted physical
examination.
Vital signs  (e.g., temperature, pulse, respi[INVESTIGATOR_1520], blood pressure while seated). Carefully
consider which vital signs (if any) should be measured to ensure that only essential data are
collected. Include any specific instructions with respect to the collection and interpretation of
vital signs.
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 44 Biological specimen collection and laboratory evaluations . Urine pregnancy test, CBC to
exclude anemic conditions, C-Peptide tests to confirm T1 diabetes and rule out T2 diabetes, and
HbA1c levels at screening. Electrocardiogram to evaluate cardiac status. Frequent BG
measurements to titrate D20% IV administration rate and keep patients in euglycemia range.
Special assays or procedures required.  Multiple plasma samples will be frozen and stored to
measure insulin levels via radioimmunoassay (RIA)
Counseling procedures, including any dietary or activity considerations :  Patients will be
trained on study procedures and will be asked to maintain their usual diet and exercise regimens
during the course of the entire study. Prior to clamp visits, however, they are asked to refrain
from strenuous exercise and eating meals high in carbohydrates.
Assessment of study intervention adherence: a CGM device will be applied to identify any
hyperglycemia or hypoglycemia.
Administration of questionnaires or other instruments will be utilized to collect pain scores
(VAS) and maintain AE records (phone visit and diary during washout period).  Additionally,
usability questionnaires will collect patient and clinician perspective on product usability to
identify sources of user error.
Assessment of adverse events.  Reported AEs and SAEs will be reviewed by [CONTACT_704516].
8.3 ADVERSE EVENTS 
8.3.1 DEFINITION OF ADVERSE EVENTS 
An Adverse Event (AE) is defined any untoward medical occurrence associated with the use of an 
intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). 
Investigational device adverse events/effects shall be reported as anticipated or unanticipated per CFR 
812.3, and drug reactions and/or adverse drug effects shall be reported as described in CFR 312.32.  
Events shall be reported to the Sponsor per protocol and to the governing IRB per IRB requirements and 
all applicable study regulations. 
A list of anticipated (expected) adverse effects related to the study device, study intervention or testing 
procedures and known complications of diabetes disease, insulin use, treatments and treatment 
equipment have been provided in reference document 150-1004-02 Feasibility Study Anticipated 
Adverse Event Definitions. 
8.3.2  SERIOUS ADVERSE EVENTS AND UNANTICIPATED ADVERSE DEVICE EFFEC TS 
A Serious Life-threatening Adverse Event or Life-threatening Suspected Adverse Reaction is defined as 
an adverse event/effect or suspected effect that is considered “life -threatening” that if, in the view of 
either the investigator or sponsor, its occurrence places the patient or participant at immediate risk of 
death. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 45 Serious adverse event (SAE) 
A serious adverse event or serious suspected adverse reaction - defined as an adverse event or 
suspected adverse reaction is considered "serious" if, in the view of either the investigator or sponsor, it 
results in any of the following outcomes: 
death, 
a life-threatening adverse event, 
inpatient hospi[INVESTIGATOR_1081], 
a persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions, 
or a congenital anomaly/birth defect. 
A suspected adverse reaction means any adverse event for which there is a reasonable possibility that 
the drug caused the adverse event. Per federal regulations "reasonable possibility" means there is 
evidence to suggest a causal relationship between the drug and the adverse event. 
Unexpected Adverse Event or Unexpected Suspected Adverse Reaction 
An unexpected adverse event/effect is defined as an adverse event or suspected adverse reaction is 
considered "unexpected" if it is not listed in the investigator brochure or is not listed at the specificity or 
severity that has been observed; or, if an investigator brochure is not required or available, is not 
consistent with the risk information described in the general investigational plan or elsewhere in the 
current application, as amended. 
Unanticipated Adverse Device Effects (UADE) 
An unanticipated adverse device effect is defined as “any serious adverse effect on health or safety or 
any life-threatening problem or death caused by, or associated with, a device, if that effect, problem, or 
death was not previously identified in nature, severity, or degree of incidence in the investigational plan 
or application (including a supplementary plan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of participants.”  
For consideration of device safety and performance, an unanticipated adverse event is an event that has 
not been described in the investigational plan, study protocol, attachments, Instructions for Use, 
product labeling, or other product descriptions including those of ancillary study products. 
A UADE must be directly related to the device under investigation. 
The Sponsor is responsible for promptly reviewing any and all information relevant to the device or drug 
product and considering the impact of the all adverse event (s) on study continuation. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 46 8.3.3  ADVERSE EVENT/EFFECT CLASSIFICATION 
All adverse events shall be classified based on their relationship to the investigational device, 
intervention or test period; underlying disease state, pre-existing co-morbidity or concomitant therapy 
as described below: 
Related  – Anticipated AE known to occur with the study intervention, there is a reasonable 
possibility that the study intervention caused the AE, or there is a temporal relationship 
between the study intervention and event. Reasonable possibility means that there is evidence 
to suggest a causal relationship between the study intervention and the AE. 
Unrelated  – Definite assessment that there is no reasonable possibility that the study 
intervention caused the event, and no defined temporal relationship between the study 
intervention and adverse event onset, or an alternate etiology has been established. 
Unknown - A determination of relationship to the product, test procedure or co-morbidity 
cannot be established. 
Not Assessable - There is insufficient data to determine a relationship to the investigational 
product, procedure or other condition. 
8.3.4  TIME PERIOD AND FREQUENCY OF ADVERSE EVENT ASSESSMENT 
Adverse event assessment and reporting shall occur continuously throughout the study. In the case of 
home use events, participants will be instructed to document issues in the provided Patient Diary and 
notify their respective study center per written instructions. Adverse events will be reviewed by a 
Medical Monitor as outlined in 10.1.6 – Safety Oversight. 
8.3.5 ADVERSE EVENT REPORTING 
A complication, adverse event (AE), serious adverse event (SAE) or Unanticipated Adverse Device effect 
(UADE) may become known to study personnel during study visits, participant interviews or during a 
study monitoring visit. 
All adverse events (including UADEs and SAES) as well as local and systemic reactions shall be captured 
on the appropriate case report form (CRF). Data must include an event description, event start time, 
severity assessment, relationship to study product, resolution or event stabilization time/date. 
NOTE: Co-morbidity and medical conditions present at baseline shall be considered pre-existing 
conditions and will not be reported as an adverse event. However, if a participant’s condition 
deteriorates at any time during the study and requires medical intervention to resolve, this shall be 
captured as a study adverse event. 
All adverse events and complications, regardless of relationship, severity or seriousness shall be fully 
documented and recorded. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957305] (UADE) or serious 
adverse event (SAEs) shall be reported to the Sponsor within 24 hours of knowledge of the event. All 
UADEs or SAEs shall be reported to the IRB either per site IRB regulations, or at a minimum, no later 
than 5 days after knowledge of the event. 
8.3.7 REPORTING ADVERSE EVENTS TO STUDY PARTICIPANTS 
Reportable events shall be reviewed and summarized in a timely manner. A report of these events shall 
be provided to the study investigators and shared with study participants at the investigator’s 
discretion. 
8.3.[ADDRESS_957306] 
In this study, hypoglycemia should not be reported as an adverse event unless it is designated as a 
Serious Adverse Event (See Section 8.3.2).  Hypoglycemic events will be collected and categorized 
according to American Diabetes Association criteria as follows: 
Level 1:  Glucose value ≤ 70 mg/dL
Level 2:  Glucose value < 54 mg/dL
Level 3:  Severe hypoglycemia associated with cognitive impairment requiring external
assistance for recovery
Level 3 hypoglycemia epi[INVESTIGATOR_704472] a serious adverse event per section 8.3.2. 
Hypoglycemia data will be collected from SMBG meter uploads, CGM data and participant diaries. 
8.3.9  REPORTING OF PREGNAN CY 
Female participants who become pregnant during the intervention or testing period shall return to the 
investigational site for a physical exam to ensure safety. Upon potential or confirmed pregnancy, female 
participant shall be exited from the study and no further testing or evaluations will be made, UNLESS 
participant is experiencing an adverse event. If participant is experiencing an adverse event related to 
study intervention or testing, the AE should be reported as above in Section 8.3.5 and participant should 
be followed until resolution or stabilization of the event. 
8.4 UNANTICIPATED PROBLE MS 
This study is considered to be a low risk device evaluation. However, if an Investigator or Sponsor 
become aware of an issue that is “Unexpected in terms of nature, severity, or frequency, or related or 
possibly related to participation in the research or puts the research participants or others at a greater 
risk of harm (including physical, psychological, economic, or social harm) than was previously known or 
recognized”, these events shall be reported to the Sponsor and governing IRB within 24 hours of 
knowledge of the event(s). 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 48 8.4.1  UNANTICIPATED ISSUE REPORTING TO IRB 
See Section 8.3 above. 
8.4.2  UNANTICIPATED ISSUE REPORTING TO PARTICIPANTS 
See Section 8.3 above. 
9 STATISTICAL CONSIDERATIONS 
A formal Statistical Analysis Plan (SAP) will be completed prior to database lock and un-blinding of the 
study data. The SAP generally includes additional statistical analysis detail (e.g., calculation of derived 
variables, data exclusion rules, listings of tables, figures and listings produced, etc.).  
9.1 STATISTICAL HYPOTHES ES 
Null Hypothesis : There is no difference in the population mean rates of decline for the Achilles
and control infusion sets, as measured by [CONTACT_704479] (s) contrast for the ln(AUC 0-300(GIR) ) assessed
over study days DOI, day 3, day 5, and day 7.
Alternative Hypothesis : The rate of decline (slope coefficient s) for the Achilles infusion set is
less that the corresponding rate for control
9.2 SAMPLE SIZE DETERMINATION 
A sample size of 24 participants is sufficient to generate 90% power for a 2-tailed p=0.[ADDRESS_957307](AUC 0-300(GIR) ) slope contrasts(=control minus Achilles), within this 2x2 crossover design.  In addition 
to the usual regularity assumptions for the 2x2 crossover design (i.e. no carryover effects), this 
computation was based on the following assumptions: 
1. The ln(AUC 0-300(GIR) )’s  are normally  distributed.
2.The within participant variance is 40% of the total variance.
3. The study day correlation matrix of the within-participant ln(AUC 0-300(GIR) ) assessments is
AR(autoregressive model) with correlation r=0.5.
4. The within plus among participant variance for the ln(AUC 0-300(GIR) )'s is 0.21 (based on previous studies).
5. The difference in slopes (Achilles minus control) is at least 0.07.
9.3 POPULATIONS FOR ANALYSES 
Intention- to-Treat (ITT) Analysis Population: all patients that meet all inclusion criteria and none of the 
exclusion criteria and are randomized to treatment sequence and complete at least one glucose clamp 
procedure will be included in the ITT population.  
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F 
Confidential Uncontrolled when printed 49 Safety Analysis Population:  all patients who had either an investigational or control cannula implanted. 
Per-Protocol (PP) Analysis Population: all patients who completed both treatment sequences with no 
major protocol violations. 
The primary effectiveness analysis will be based on the ITT participant population. Sensitivity analyses of 
the primary effectiveness endpoint will be generated based on the PP population. The ITT population 
may contain some patients that complete the first treatment, but not the second, and vice versa. This 
will require the use of imputation methods for missing values, which are documented in Section 9.4.2.  
The primary safety analysis will be based on the Safety population. All secondary and exploratory 
effectiveness analyses will use the PP population. 
9.[ADDRESS_957308]. Data that is highly skewed or contains 
outliers even after the log transformation will be analyzed using the rank transformation, namely 
analyzing the ranks of the assessments within the combined sample. The paired measurements will be 
analyzed with dependent t tests or Wilcoxon signed rank tests, as indicated.  AUC data will be calculated 
with the trapezoidal rule for defined PK/PD time points. Post hoc analyses will be performed after 
confirmation of significant main effects. Unless otherwise specified, data will be reported as mean ± SD 
with p<0.05 considered statistically significant. 
A data convention used in this analysis is as follows: for tabulated continuous variables, the descriptive 
analyses will present the mean, standard deviation, median, minimum and maximum. And for tabulated 
categorical variables, the number with the characteristic, the total number evaluated, the percent and 
the 95% Wilson Score confidence intervals will be provided. 
For secondary endpoint analyses, two-tailed significance tests will be performed with significance level 
p=0.05. 
For the estimation of catheter failures, we used data from the study of Patel et al. who investigated 
steel and Teflon infusion sets worn over a 7-day period.5 They reported that 42% of participants could 
consistently wear an infusion set for 6-7 days (58% failure) without a deterioration in glucose levels.  It 
should be noted that their failure rate also included accidental removal of catheters, removal due to 
pain, and removal due to poor adhesion of catheter pad (total 32%).  Since our participants will be in a 
more controlled setting (i.e. clinical research staff will be inserting and carefully securing the devices 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 50 using an aseptic technique), we anticipate having lower failure rates related to early catheter removal.  
We therefore assume a 40-50% failure rate to be a reasonable estimate of total anticipated failures and 
have added 6 additional participants for an anticipated total sample size of n=30. (Statistical analyses 
were performed using Systat version 13.) 
9.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S) 
The ln(AUC 0-300(GIR) )  on DOI (day 0) and days 3, 5, 7, periods 1 and 2  will be calculated using the 
trapezoidal rule.  A mixed-effects (repeated-measures) linear model with treatment and period as fixed 
effects and participant as a random effect will then be fit to this data.  Estimates of the slopes by 
[CONTACT_704517].  Treatment comparisons 
and confidence bounds on the difference in slopes will be presented. Details will be provided in the 
Statistical Analysis Plan  
The natural log of each AUC mean slopes for the two treatment groups will be compared in a mixed-
effects (repeated-measures) linear model with treatment and period as fixed effects and participant as a 
random effect. 
The primary analysis will be conducted on the ITT population; the mixed-effects model accounts for 
missing data using a missing at random (MAR) assumption, which will be checked.  
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINT(S) 
Secondary analyses will use the both ITT and PP populations for analysis.  
The survival of the Achilles and control infusion sets will be compared using a discrete lifetable analysis 
over study days 0, 3, 5, and [ADDRESS_957309]. 
All pharmacokinetic parameters (AUCs, t 50, C max, tmax, MRT for the insulin concentration by [CONTACT_454353], 
etc.) will be estimated using non-compartmental models and log-transformed before analysis.  Means 
for the two treatment groups will be compared in a mixed-effects (repeated-measures) linear model 
with treatment and period as fixed effects and participant as a random effect.  The mean difference 
between treatments (on the log-scale) will be compared with a two-sided test using significance level 
α=0.05. Then mean ratio and its 95% confidence interval will be calculated by [CONTACT_704518] -transforming the 
mean difference and its 95% confidence interval.   
All pharmacodynamic parameters (AUCs, onset time and time to return to baseline for the glucose 
concentration by [CONTACT_454353], etc.) will be estimated using non-compartmental models.  Means for the 
two treatment groups will be compared in a mixed-effects (repeated-measures) linear model with 
treatment and period as fixed effects and participant as a random effect.  The mean difference between 
treatments will be compared with a two- sided test using significance level α=0.05.  Wilcoxon signed rank 
tests will be used if the data is significantly skewed.   
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 51 9.4.4  SAFETY ANALYSES 
Tolerability of infusion sets will be assessed by [CONTACT_704519] 7 of use with a mixed-effects (repeated-measures) linear model with treatment, period and 
day as fixed effects and participant as a random effect.  The mean difference between treatments will 
be compared with a two- sided test using significance level α=0.05.   
Adverse events (AEs) will be coded using CTCAE v4.0.  Descriptive statistics (number of participants and 
per-participant incidence) for device-related AEs will be presented by [CONTACT_1196], Preferred 
term, severity and treatment.  Unanticipated and serious device-related AEs will be presented 
separately by [CONTACT_3148]. 
9.4.5  BASELINE DESCRIPTIVE STATISTICS 
The following baseline variables and demographics will be compared for the two randomization groups:  
age, gender, race, ethnicity, baseline HbA1c, and BMI category. 
9.4.[ADDRESS_957310] completed the study. 
Futility is defined as a participant incidence of >5 SAEs, a failure rate of >90% on Day 5 for the 
investigational infusion set, or a forecasted probability of primary endpoint success at the end of the 
trial that is too low to justify continuing. 
9.4.7  SUB-GROUP ANALYSES 
N/A 
9.4.8  TABULATION OF INDIVIDUAL PARTICIPANT DATA 
Listings of the primary and secondary endpoints will be presented by [CONTACT_704520]   
9.4.9  EXPLORATORY ANALYSES 
Exploratory analyses will use the both ITT and PP populations for analysis.  All pharmacokinetic 
parameters (AUCs, t 50, Cmax, tmax, MRT for the insulin concentration by [CONTACT_454353], etc.) will be estimated 
using non-compartmental models and log-transformed before analysis.  Means for the two treatment 
groups will be compared in a mixed-effects (repeated-measures) linear model with treatment, day and 
period as fixed effects and participant as a random effect.  The mean difference between treatments (on 
the log-scale) will be compared with a two-sided test using significance level 0.05.  Then mean ratio and 
its 95% confidence interval will be calculated by [CONTACT_704518]-transforming the mean difference and its 95% 
confidence interval.  Trends over time within treatments will be compared with two-sided tests using 
significance level α=0.05.  
Kaplan-Meier device survival curves will be constructed for each device and then compared with a Cox 
regression analysis with a frailty term that accounts for the repeated-measures on participants. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957311] comply with applicable 
regulatory requirements (e.g., 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56) and should adhere to ICH 
GCP. Prior to the beginning of the trial, the investigator s hould have the IRB’s written approval for the 
protocol and the written informed consent form(s) and any other written information to be provided to 
the participants.  
[IP_ADDRESS]  CONSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS 
The consent form contains all required regulatory elements.  
[IP_ADDRESS]  CONSENT PROCEDURES AND DOCUMENTATION 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation.  Consent forms will be Institutional 
Review Board (IRB)-approved and the participant will be asked to read and review the document. The 
investigator will explain the research study to the participant and answer any questions that may arise. 
A verbal explan ation will be provided in terms suited to the participant’s comprehension of the 
purposes, procedures, and potential risks of the study and of their rights as research participants.  
Participants will have the opportunity to carefully review the written consent form and ask questions 
prior to signing. The participants should have the opportunity to discuss the study with their family or 
surrogates or think about it prior to agreeing to participate. The participant will sign the informed 
consent document prior to any procedures being done specifically for the study. Participants must be 
informed that participation is voluntary and that they may withdraw from the study at any time, without 
prejudice. A copy of the informed consent document will be given to the participants for their records. 
The informed consent process will be conducted and documented in the source document (including the 
date), and the form signed, before the participant undergoes any study-specific procedures. The rights 
and welfare of the participants will be protected by [CONTACT_21223]. 
[IP_ADDRESS]  STUDY DISCONTINUATION AND CLOSURE 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be 
provided by [CONTACT_704521], investigator, and sponsor.  If the study is prematurely 
terminated or suspended, the Principal Investigator (PI) will promptly inform study participants, the 
Institutional Review Board (IRB), and will provide the reason(s) for the termination or suspension.  Study 
participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 53 Circumstances that may warrant termination or suspension include, but are not limited to: 
Determination of unexpected, significant, or unacceptable risk to participants
Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]
Insufficient compliance to protocol requirements
Data that are not sufficiently complete and/or evaluable
Determination that the primary endpoint has been met
Determination of futility
Three or more participants develop DKA
Three or more participants develop severe hypoglycemia
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the sponsor, and IRB. 
10.1.[ADDRESS_957312] by [CONTACT_3486], their 
staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover testing of 
biological samples and genetic tests in addition to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the sponsor.  
All research activities will be conducted in as private a setting as possible. 
The study monitor, other authorized representatives of the sponsor, representatives of the Institutional 
Review Board (IRB), regulatory agencies or pharmaceutical company supplying study product may 
inspect all documents and records required to be maintained by [CONTACT_093], including but not 
limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this 
study. The clinical study site will permit access to such records. 
The study participant’s contact [CONTACT_21225]. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by [CONTACT_3488], Institutional policies, or sponsor requirements. 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 
be transmitted to and stored at the Sponsor. This will not include the participant’s contact [CONTACT_46203]. Rather, individual participants and their research data will be identified by a unique study 
identification number. The study data entry and study management systems used by [CONTACT_704522]. At the end of the study, all study 
databases will be de-identified and archived at the Sponsor. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957313] to 
biosample storage may not be possible after the study is completed.  
When the study is completed, access to study data and/or samples will be provided through the 
Sponsor. 
10.1.[ADDRESS_957314] information of the PI [INVESTIGATOR_704473] 9. 
Table 9: Study Governance 
Principal Investigator  [INVESTIGATOR_704474]  S Bailey,  MD 
President  & CEO,  AMCR  Institute  
625 W. Citracado  Pkwy,  # 112 
Escondido,  CA [ZIP_CODE]  
Telephone:  [PHONE_14684]  
E-mail:
[EMAIL_13474] Muchmore, MD  
Senior Clinical Advisor  
Capi[INVESTIGATOR_171642], Inc.  
2 Wrigley, Ste 100  
Irvine, CA [ZIP_CODE]  
Telephone: ( [PHONE_14685]                
1. E-mail:
doug.muchmore
@capi[INVESTIGATOR_704475].co
mRayhan Lal, MD  
Clinical Instructor  
Endocrinology Academic Office, 
Stanford University  
[ADDRESS_957315], CA, [LOCATION_003] [ZIP_CODE] -5208  
Telephone:  [PHONE_14686]  
E-mail: [EMAIL_13475]
10.1.[ADDRESS_957316] monthly by [CONTACT_704523].  Sponsor Medical 
Monitor will be a licensed clinician, e.g., MD, DO, PA, or RN.  SAEs will be assessed by [CONTACT_704524]. 
Upon review of the report, an adjudication will be issued: no action may be taken, the consent form may 
be revised, study procedures may be modified, or approval of the study may be suspended, pending 
further inquiry. 
The qualifications of the Medical Monitor must be provided to NIDDK for approval. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957317] of 
the trial is in compliance with the currently approved protocol/amendment(s), with International 
Conference on Harmonization Good Clinical Practice (ICH GCP), and with applicable regulatory 
requirement(s).  
Monitors will be appointed by [CONTACT_171703][INVESTIGATOR_171642].  Monitors will be trained with scientific and/or 
clinical knowledge and his/her qualifications will documented. The Monitor will be familiar with the 
investigational product, protocol, consent form and any other written information given to the 
participant, sponsor’s SOPs, and GCP and the relevant regulatory requirements.   
Monitoring will be conducted with a combination of remote monitoring and on-site from time to time 
based on enrollment rate, occurrence of adverse events, etc. to assess ICF, eligibility, AE, device 
accountability, and primary endpoint data as further defined in the Monitoring Plan.  Sponsor 
management will be provided copi[INVESTIGATOR_10376] [ADDRESS_957318], data and biological 
specimen collection, documentation and completion.   
Quality control (QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated. Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resolution. 
Following written Standard Operating Procedures (SOPs), the monitors will verify that the clinical trial is 
conducted and data are generated and biological specimens are collected, documented (recorded), and 
reported in compliance with the protocol, International Conference on Harmonization Good Clinical 
Practice (ICH GCP), and applicable regulatory requirements.  
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_21229]. 
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957319] KEEPI[INVESTIGATOR_1645] 
[IP_ADDRESS]  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported.   
All source documents should be completed in a neat, legible manner to ensure accurate interpretation 
of data.   
Hardcopi[INVESTIGATOR_21193].  Data recorded in the electronic case report 
form (eCRF) derived from source documents should be consistent with the data recorded on the source 
documents.  
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse reactions 
data) and clinical laboratory data will be entered into EDC, a [ADDRESS_957320] protection and internal quality 
checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or 
inaccurate. Clinical data will be entered directly from the source documents. 
[IP_ADDRESS]  STUDY RECORDS RETENTION 
The investigator(s) will retain all study records for a minimum of 15 years from the date of Federal 
Financial Report submission. No records will be destroyed without the written consent of the sponsor 
(Capi[INVESTIGATOR_171642], Inc.). The sponsor will inform the investigator(s) when the study records are no 
longer need to be retained. 
10.1.9  PROTOCOL DEVIATIONS 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonization Good Clinical Practice (ICH GCP), or Manual of Procedures (MOP) requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a 
result of deviations, corrective actions are to be developed by [CONTACT_3483].  
These practices are consistent with ICH GCP: 
•4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3
•5.1 Quality Assurance and Quality Control, section 5.1.1
•5.[ADDRESS_957321] be addressed in study source documents, reported to the sponsor.  The site 
investigator is responsible for knowing and adhering to the reviewing IRB requirements. Further details 
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 57 about the handling of protocol deviations will be included in the MOP. Deviations involving risk to 
participants will be reported to the IRB and the sponsor within 10 working days. 
10.1.10  PUBLICATION AND DATA SHARING POLICY 
The clinical trial investigators will determine the authorship of peer publications based upon the work 
effort performed.  Data and samples/specimen are owned by [CONTACT_704525]. 
10.1.[ADDRESS_957322] Committee and establish/implement a plan to manage 
the conflict. 
10.[ADDRESS_957323] 
IB Investigator’s Brochure  
ICH International Conference on Harmonisation 
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IND Investigational New Drug Application  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
ISO International Organization for Standardization  
ITT Intention -To-Treat  
IV Intravenous  
LSMEANS  Least -squares Means  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
NCT National Clinical Trial  
NIH National Institutes of Health  
NIH IC  NIH Institute or Center  
OHRP  Office for Human Research Protections  
PI [INVESTIGATOR_704476](ly)  
SMBG  Self-monitored Blood Glucose  
SMC  Safety Monitoring Committee  
SOA  Schedule of Activities  
SOC System Organ Class  
SOP Standard Operating Procedure  
UP Unanticipated Problem  
US [LOCATION_002]  
VAS Visual Analogue Scale  
Capi[INVESTIGATOR_171642], Inc. 150-1022-00 Rev F
Confidential Uncontrolled when printed 59 10.3 PROTOCOL AMENDMENT HISTORY 
The table below is intended to capture changes of IRB-approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
Version  Date  Description of Change Brief Rationale  
A 2/12/2020  Initial release  As submitted to FDA  
B 3/19/2020  Respond to FDA requests  IDE G190079 -S001 approved  
C 4/16/2020  Clarify clamp procedures, extend 
screening time duration and allow 
Dexcom G6 run -in period  Support recruitment at Study 
Center during COVID -19 
D 7/20/2020  Revised blood sampling schedule and 
clarified other procedure s; specified 
independent safety monitor  Align to Study Center procedure  
E 10/15/2020  Increased basal stabilization period from 
maximum of 3.0 to 3.5 hours and 
revised glucose infusion “trigger” value 
during euglycemic clamp from 90 mg/dL 
to be a value 5 mg/dL less than the 
mean of the t hree  values obtained 
during Baseline Period II  These changes improve the 
likelihood of achieving a stable 
baseline prior to initiating the 
clamp procedure and also reduce 
the risk of hypoglycemic overshoot 
in the early phase of the clamp 
procedure  
F 11/24/2020  Clarify procedure; added one time 
rescreen for A1C and C -peptide  Align to Study Center procedure; 
Capi[INVESTIGATOR_171642]’s standard 
procedure has been to allow for a 
single rescreen attempt for key 
labs (e.g. A1C and c -peptide).  
Capi[INVESTIGATOR_171642], Inc. 150-1022-[ADDRESS_957324]. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol.  16,
730– 745 (2010).
2. Sampson Perrin, A. J. et al.  A Web-Based Study of the Relationship of Duration of Insulin Pump Infusion Set
Use and Fasting Blood Glucose Level in Adults with Type 1 Diabetes. Diabetes Technol. Ther.  17, 307– 310
(2015).
3. Walsh, J., Roberts, R., Weber, D., Faber-Heinemann, G. & Heinemann, L. Insulin Pump and CGM Usage in
the [LOCATION_002] and [LOCATION_013]: Results of a Real-World Survey With 985 Participants. J. Diabetes Sci.
Technol.  9, 1103 –10 (2015).
4. Schmid, V., Hohberg, C., Borchert, M., Forst, T. & Pfützner, A. Pi[INVESTIGATOR_704477]-trouble starts on day 3. J. diabetes Sci. Technol.
4, 976–982 (2010).
5. Patel, P. J. et al.  Randomized Trial of Infusion Set Function: Steel Versus Teflon. Diabetes Technol. Ther.  16,
1–5 (2013).
6. Swan, K. L. et al.  Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic
Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy. Diabetes
Care  32, 240–244 (2009).
7. Pfützner, A. et al.  Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads
to a High Risk for Adverse Events: Results From a Prospective Randomized Crossover Study. J. Diabetes Sci.
Technol.  9, 1292 –8 (2015).
8. Heinemann, L. & Krinelke, L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin
infusion. J. Diabetes Sci. Technol.  6, 954– 964 (2012).
9. Clarke, W. L. & Renard, E. Clinical requirements for closed-loop control systems. J. Diabetes Sci. Technol.  6,
444– 52 (2012).
10. Boetticher, M. et al.  Comparison of Dead to Live Porcine Tissue for Determination of Subcutaneous Insulin
Absorption Patterns Using Micro-CT Imaging. FAER Symposium  (2016).
11. Diaz, D. et al.  Histology and Micro-CT Imaging of Insulin Bolus through CSII cannulas in Swine: A Time-
Course Study of Insulin Distribution over Seven Days. (2017).
12. Diaz, D. et al.  Micro-CT Imaging of an Insulin Bolus Infusion through a Commercial Continuous
Subcutaneous Insulin Infusion (CSII) cannulas in Live Swine: A Time Course Study of Distribution Patterns.
(2016).
13. Liebner, T. et al.  Insulinpumpenkatheter – Komplikationen im Kindes- und Jugendalter. Diabetol. und
Stoffwechsel  5, P151 (2010).
14. Renard, E., Guerci, B., Leguerrier, A.-M. & Boizel, R. Lower rate of initial failures and reduced occurrence of
adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-
period, observational, multicenter study . Diabetes Technol. Ther.  12, 769–773 (2010).
15. van Bon, A. C., Bode, B. W., Sert-Langeron, C., DeVries, J. H. & Charpentier, G. Insulin Glulisine Compared to
Insulin Aspart and to Insulin Lispro Administered by [CONTACT_704526][INVESTIGATOR_171642], Inc. 150-1022-00 Rev F 
Confidential Uncontrolled when printed 61 with Type 1 Diabetes: A Randomized Controlled Trial. Diabetes Technol. Ther.  13, 607– 614 (2011). 
16. Clausen, T. S., Kaastrup, P. & Stallknecht, B. Effect of insulin catheter wear-time on subcutaneous adipose
tissue blood flow and insulin absorption in humans. Diabetes Technol. Ther.  11, 575–580 (2009).
17. Vaughn, D. E. & Muchmore, D. B. Use of recombinant human hyaluronidase to accelerate rapid insulin
analogue absorption: experience with subcutaneous injection and continuous infusion. Endocr. Pract.  17,
914– 21
18. Luijf, Y. M. et al.  Patch pump versus conventional pump: postprandial glycemic excursions and the
influence of wear time. Diabetes Technol. Ther.  15, 575 –9 (2013).
19. Ruan, Y. et al.  Faster insulin action is associated with improved glycaemic outcomes during closed-loop
insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes. Diabetes. Obes.
Metab.  19, 1485 –1489 (2017).
20. Mader, J. K. et al.  Enhanced Absorption of Insulin Aspart as the Result of a Dispersed Injection Strategy
Tested in a Randomized Trial in Type 1 Diabetic Patients. Diabetes Care  36, 780– 785 (2013).
21. Edsberg, B., Herly, D., Hildebrandt, P. & Kühl, C. Insulin bolus given by [CONTACT_704527]: effect on
absorption and glycaemic response to a meal. Br. Med. J. (Clin. Res. Ed).  294,  1373– 1376 (1987).
22. Ruan, Y. et al.  Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults
With Type 1 Diabetes. Diabetes Care  39, 830–832 (2016).
23. Grunberger, G. et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE
OF ENDOCRINOLOGY [ADDRESS_957325].  24, 302– 308
(2018).
24. Corr, D. T. & Hart, D. A. Biomechanics of Scar Tissue and Uninjured Skin. Adv. wound care  2, 37–43 (2013).
25. Conwell, L. S. et al.  Dermatological complications of continuous subcutaneous insulin infusion in children
and adolescents. J. Pediatr.  152,  622–8 (2008).
26. Skyler, J. S. Continuous Subcutaneous Insulin Infusion-an Historical Perspective. Diabetes Technol. Ther.  [ADDRESS_957326] 1, S5-9 (2010).
27. Kildegaard, J., Christensen, T. F. & Hejlesen, O. K. Sources of glycemic variability --what type of technology is
needed? J. diabetes Sci. Technol.  3, 986–991 (2009).
28. Mader, J. K. et al.  Enhanced absorption of insulin aspart as the result of a dispersed injection strategy
tested in a randomized trial in type 1 diabetic patients. Diabetes Care  36, 780 –5 (2013).
29. Perrier, D. & Gibaldi, M. General derivation of the equation for time to reach a certain fraction of steady
state. J. Pharm. Sci.  71, 474–5 (1982).